Shack Herbert Michael Form PRRN14A September 16, 2008

# PRELIMINARY PROXY STATEMENT

# SCHEDULE 14A INFORMATION (RULE 14a-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 1

Filed by the Registrant [ ]
Filed by a Party other than the Registrant [X]
Check the appropriate box: [X] Preliminary Proxy Statement
[ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive Proxy Statement
<ul><li>[ ] Definitive Additional Materials</li><li>[ ] Soliciting Material Under Rule 14a-12</li></ul>
ARTES MEDICAL, INC.
(Name of Registrant as Specified in Charter)
H. MICHAEL SHACK
(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)
Payment of Filing Fee (Check the appropriate box):
<ul><li>[X] No fee required.</li><li>[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.</li></ul>
(1) Title of each class of securities to which transaction applies:
(2) Aggregate number of securities to which transaction applies:
(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:
[ ] Fee paid previously with preliminary materials.
[ ] Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
<ul><li>(1) Amount Previously Paid:</li><li>(2) Form, Schedule or Registration Statement No.:</li><li>(3) Filing Party:</li><li>(4) Date Filed:</li></ul>

#### PRELIMINARY COPY

#### 2008 ANNUAL MEETING OF STOCKHOLDERS

OF

ARTES MEDICAL, INC.

PROXY STATEMENT

OF

#### H. MICHAEL SHACK

To All Artes Medical, Inc. Stockholders:

This Proxy Statement and the accompanying blue proxy card are being furnished to stockholders ("Stockholders") of Artes Medical, Inc. (the "Company") in connection with the solicitation of proxies by H. Michael Shack (the "Proxy Organizer") to be used at the annual meeting (the "Annual Meeting") of Stockholders of the Company which, pursuant to the bylaws of the Company, should have been called during the first quarter of 2008. Since the original filing of this Proxy Statement, the Company has scheduled the Annual Meeting for October 30, 2008, at the San Diego Marriott Del Mar located at 11966 El Camino Real, San Diego, California 92130 at 9:00AM. The Company's principal executive offices are located at 5870 Pacific Center Blvd., San Diego, California 92121. This Proxy Statement and the blue proxy card are first being furnished to Stockholders on or about September 22, 2008.

At the Annual Meeting, the Proxy Organizer will seek to:

- 1. Amend the Bylaws of the Company (the "Bylaws") to allow a majority of the Stockholders to fill vacancies on the Board of Directors resulting from the removal of any Directors;
- 2. Amend the Bylaws to increase the number of Directors of the Company to 11;
- 3. Remove three of the current Directors of the Company under Delaware Corporations Law §141(k)(1) for cause;
- 4. Elect four new Directors to fill the newly created directorships pursuant to proposal #2 of this Proxy Statement or, in the alternative, if proposal #2 is defeated, elect three new Directors to fill the three vacancies created by the removal contained in Proposal #3 of this Proxy Statement;
- 5. Vote on the election of two new Class II Directors to serve for three year terms until the annual meeting of Stockholders in 2011 or until their successors are duly elected and qualified; and

6. Vote on the Nominees' proposal that the Company may sell up to \$20,000,000 of its securities to investors from time to time pursuant to one or more financing transactions.

The Board of Directors is currently comprised of seven members. The Proxy Organizer is seeking to increase the number of Directors to 11, remove three Directors, and then fill six seats on the Board of Directors through this Proxy. The Proxy Organizer's nominees are named below under "Election of Directors." Each of the nominees (each a "Nominee" and, collectively, the "Nominees") have been selected by the Proxy Organizer.

The Proxy Organizer is not satisfied with the existing management or Board of Directors of the Company. He believes that the Company's poor financial performance, lack of expressed business plan, and questionable changes to key personnel, all as described in the Company's quarterly and annual reports filed with the Securities and Exchange Commission (the "SEC"), are impairing the Company's ability to maximize value for all shareholders.

Section 6.9 of Article 6 of the Bylaws provides that the Bylaws may be amended by the vote of Stockholders. The Proxy Organizer's proposed amendment to the Bylaws, if approved, will allow vacancies of the Board of Directors to be filled by the vote of a majority of the outstanding shares entitled to vote. Each director so elected shall hold office until the next annual meeting for the class of each Director of the Company and until a successor has been elected and qualified.

The Proxy Organizer believes that, for the reasons stated below, there is sufficient cause to remove the Directors and it is in the best interest of all of the Stockholders to elect the six new Directors to the Company who provide a track record of success in the dermal filler market and who are experienced in developing a variety of opportunities for the Company and forging a clear direction for the Company. The Proxy Organizer believes that the proposed new Directors provide the necessary industry knowledge in the wrinkle filler markets and will provide a strong sales and marketing background to the Company. ACCORDINGLY, THE PROXY ORGANIZER IS SOLICITING PROXIES IN FAVOR OF:

- 1. Amending the bylaws to allow a majority of shareholder to fill vacancies and newly created directorships on the Board of Directors;
- 2. Amending the bylaws to increase the number of Directors to 11;
- 3. Remove three of the current Directors for cause;
- 4. Elect four new Directors to fill the newly created directorships pursuant to proposal #2 of this Proxy Statement or, in the alternative, if proposal #2 is defeated, elect three new Directors to fill the three vacancies created by the removal contained in Proposal #3 of this Proxy Statement;
- 5. Vote on the election of two new Class II Directors to serve for three year terms until the annual meeting of Stockholders in 2011 or until their successors are duly elected and qualified; and

6. Vote on the Nominees' proposal that the Company may sell up to \$20,000,000 of its securities to investors from time to time pursuant to one or more financing transactions.

What went wrong with Artes Medical?

- According to the NASDAQ Stock Exchange, the Company's stock price has declined more than 88% in the last 52 weeks. Within this time period, the Company's market value has declined from \$134.5 million to approximately \$15 million, erasing a staggering \$119.5 million in shareholder value. The Company's share price reached an all-time low of \$0.35 on September 16, 2008, down from an all-time high of \$9.96 in February 2007.
- According to the Company's Current Report on Form 8-K filed with the SEC on August 22, 2008, on August 19, 2008, the Company received a notice from NASDAQ indicating that its stockholders' equity on June 30, 2008 was less than the \$10 million required for continued listing on The NASDAQ Global Market under Marketplace Rule 4450(a)(3).
- According to the Board of Directors' biographies in the Company's annual report filed with the SEC, the Company's current Board of Directors lack any specific industry expertise in the personal aesthetics market.
- According to the Company's reports filed with the SEC, the Board of Directors has made significant personnel changes to the senior management team that had grown the Company from a struggling medical technology start-up to an IPO candidate with a world class, FDA-approved dermal filler product Artefill, replacing them with a management team with little or no relevant industry experience in the dermal filler market.
- According to the Company's reports filed with the SEC, the Company has pledged ALL of its assets against a \$22.5 million revenue financing entered into with COWEN Healthcare Royalty Partners ("CHRP") in January 2008. All assets of Artes Medical will revert to CHRP in case of Artes Medical's default to service future royalty obligations.
  - The Company's management has not acted in a fiscally responsible manner because, among other things, the Company is running out of cash due to, as the Proxy Organizer believes, excessive spending at a rate of approximately \$3 million per month as outlined in the financial statements of the Company's quarterly and annual filings with the SEC.
- According to the Company's reports filed with the SEC, the Company has failed to capitalize on other uses of Artefill beyond personal aesthetics as a means of generating additional opportunities and cash flow for the Company.
- The current management and Board of Directors are responsible for canceling a signed distribution agreement on March 5, 2007 with a Taiwanese corporation that would have given the Company a minimum of \$4.2 million in combined revenues from sales of Artefill in Taiwan during the first two years of the contract alone.

- The current management and Board of Directors are responsible for forfeiting an estimated minimum of \$20 million in additional future royalty revenues from Bioform Medical over the lifetime of the Company's '452 core technology patent by settling for one lump sum payment of \$5.5 million which generated a one-time only increase in revenues for the third quarter in 2007 as outlined in the financial statements of the Company's quarterly and annual filings with the SEC.
- According to the 2007 statistics of the American Society For Aesthetic Plastic Surgery ("ASAPS"), the market penetration of Artefill was a dismal 0.7% in 2007 compared to its closest competitor's 7% for Radiesse® semi-permanent filler marketed by Bioform Medical. The target number of patients treated with Artefill in year two was initially forecasted at 40,000 patients, however, as indicated in a press release by the Company dated July 28, 2008, only 10,000 patients have been treated within the first 18 months since ArteFill's U.S. market introduction.

How the new Board of Directors proposes to turn the Company around:

- 1. Engage new senior management to provide leadership and re-establish enthusiasm and morale among employees as well as credibility among customers and the financial community;
- 2. Focus on near-term break-even in the fourth quarter of 2009 through increases in ArteFill sales as well as a significant reduction of cost of goods and operating expenses;
- 3. Implement new and creative sales and marketing strategies for Artefill to reach more aggressive revenue forecasts;
- 4. Create 'ArteFill Centers of Excellence' within key opinion leaders private practices and organize nationwide and international hands-on, peer-to-peer ArteFill training seminars engaging physician opinion leaders to re-establish scientific credibility and overcome widespread misconception regarding the use of ArteFill and competitor's discreditation of ArteFill;
  - 5. Pursue international market opportunities for Artefill;
  - 6. Remove skin test requirements for ArteFill in collaboration with the FDA;
- 7. Develop next generation injectable dermal filler and expand Company's product portfolio through in-licensing of new and exciting anti-aging technologies; and
- 8. Pursue medical pipeline indications such as heartburn (GERD) and spinal disk repair with the Company's platform technology.

THE NOMINEES ARE COMMITTED TO ACTING IN THE BEST INTERESTS OF THE STOCKHOLDERS.

REPRESENTATIVES OF THE NEWLY PROPOSED BOARD OF DIRECTORS AND THEIR PROPOSED CHIEF FINANCIAL OFFICER, WILLIAM KACHIOFF, WILL EXPLAIN THEIR TURN-AROUND STRATEGY AND FINANCIAL MODEL IN MORE DETAIL AT THE ANNUAL MEETING.

THE PROXY ORGANIZER BELIEVES THAT YOUR VOICE IN THE FUTURE OF THE COMPANY CAN BEST BE EXPRESSED THROUGH THE ELECTION OF THE NOMINEES. ACCORDINGLY, THE PROXY ORGANIZER URGES YOU TO VOTE YOUR BLUE PROXY CARD FOR THE NOMINEES.

IF YOUR SHARES ARE HELD IN THE NAME OF A BROKERAGE FIRM, BANK, BANK NOMINEE OR OTHER INSTITUTION ON THE RECORD DATE, ONLY IT CAN VOTE SUCH SHARES AND ONLY UPON RECEIPT OF YOUR SPECIFIC INSTRUCTIONS. ACCORDINGLY, PLEASE CONTACT THE PERSON RESPONSIBLE FOR YOUR ACCOUNT AND INSTRUCT THAT PERSON TO EXECUTE ON YOUR BEHALF THE BLUE PROXY CARD AS SOON AS POSSIBLE.

#### **IMPORTANT**

The election of the Nominees requires the affirmative vote of a PLURALITY of the votes cast, assuming a quorum is present or otherwise represented at the Annual Meeting. As a result, your vote is extremely important in deciding the future of the Company. The Proxy Organizer urges you to mark, sign, date and return the enclosed blue proxy card to vote for the election of the Nominees.

THE PROXY ORGANIZER URGES YOU NOT TO SIGN ANY PROXY CARD SENT TO YOU BY THE COMPANY. IF YOU HAVE ALREADY DONE SO, YOU MAY REVOKE YOUR PROXY BY DELIVERING A LATER-DATED BLUE PROXY CARD TO THE PROXY ORGANIZER, OR BY VOTING IN PERSON AT THE ANNUAL MEETING. SEE "VOTING PROCEDURES" AND "PROXY PROCEDURES" BELOW.

Only holders of record of the Company's voting securities as of the close of business on October 1, 2008 (the "Record Date") are entitled to notice of and to vote at the Annual Meeting and any adjournments or postponements thereof. According to the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2008, filed with the SEC on May 12, 2008, as of March 31, 2008, there were 16,514,163 shares of common stock outstanding and no shares of preferred stock outstanding. Stockholders of record at the close of business on the Record Date will be entitled to one vote at the Annual Meeting for each share of common stock (the "Common Stock") held on the Record Date.

As of September 8, 2008, the Proxy Organizer beneficially owned an aggregate of 171,096 shares of Common Stock, representing approximately 1.04% of the outstanding shares of Common Stock. The Proxy Organizer intends to vote such shares "for" all proposals described in this Proxy Statement. According to the Company's SEC filings, most of its shareholders own less than 1% of the Company's common stock.

VOTE FOR ALL PROPOSALS BY RETURNING YOUR COMPLETED BLUE PROXY CARD TODAY. If you have any questions, you can reach the Proxy Organizer's proxy solicitation firm of MacKenzie Partners, Inc. at (212) 929-5500 or via e-mail at proxy@mackenziepartners.com.

#### BACKGROUND OF THE PROXY SOLICITATION

Proxy Organizer is submitting proposals for this Proxy Statement which the Proxy Organizer is independently financing. The Proxy Organizer believes that independently financed proxy solicitations do not require the Company's approval for submission to the Securities and Exchange Commission or for submission to the Company's shareholders for a vote on the proposals in Proxy Organizer's Proxy Statement at the Company's Annual Meeting. Proxy Organizer believes this Proxy Statement complies with all substantive and procedural requirements of Article II, Section 2.1 and Section 141(k) of the Delaware General Corporation Law. Under Delaware General Corporation Law Section 222(a), Proxy Organizer believes that Proxy Organizer is able to raise for the first time and to present any proposals he desires at the Annual Meeting.

In opposition to the current Board of Directors of the Company, the Proxy Organizer is seeking to solicit the proxies of Stockholders to be used to:

- 1. Amend the bylaws to allow a majority of shareholder to fill vacancies and newly created directorships on the Board of Directors;
- 2. Amend the bylaws to increase the number of Directors to 11;
- 3. Remove three of the current Directors for cause;
- 4. Elect four new Directors to fill the newly created directorships pursuant to proposal #2 of this Proxy Statement or, in the alternative, if proposal #2 is defeated, elect three new Directors to fill the three vacancies created by the removal contained in Proposal #3 of this Proxy Statement; and
- 5. Vote on the election of two new Class II Directors to serve for three year terms until the annual meeting of Stockholders in 2011 or until their successors are duly elected and qualified.
- 6. Vote on the Nominees' proposal that the Company may sell up to \$20,000,000 of its securities to investors from time to time pursuant to one or more financing transactions.

The Nominees, if elected, plan to change the existing management and operations of the Company to effectuate the plan described in this Proxy Statement. Each of the Nominees has consented to being named in the Proxy Statement, and if so elected, to serve as a Director and is fully committed, if elected, to take such action as the Nominees deem advisable and in the best interests of the Stockholders and which they believe will maximize stockholder value and improve the Company's future viability and growth.

#### PROPOSAL #1 - FIRST AMENDMENT TO THE BYLAWS

The Company's Bylaws currently contain this provision:

3.3 Vacancies. Vacancies and newly created directorships resulting from any increase in the authorized number of directors elected by all of the stockholders having the right to vote as a single class may be filled by a majority of the directors then in office, although less than a quorum, or by a sole remaining director. Whenever the holders of any class or classes of stock or series thereof are entitled to elect one or more directors by the provisions of the certificate of incorporation, vacancies and newly created directorships of such class or classes or series may be filled by a majority of the directors elected by such class or classes or series thereof then in office, or by a sole remaining director so elected. The directors so chosen shall hold office until the next annual election and until their successors are duly elected and shall qualify, unless sooner displaced. If there are no directors in office, then an election of directors may be held in the manner provided by statute. If, at the time of filling any vacancy or any newly created directorship, the directors then in office shall constitute less than a majority of the whole Board (as constituted immediately prior to any such increase), the Court of Chancery may, upon application of any stockholder or stockholders holding at least ten percent (10%) of the total number of shares at the time outstanding having the right to vote for such directors, summarily order an election to be held to fill any such vacancies or newly created directorships, or to replace the directors chosen by the directors then in office as aforesaid.

This means that upon the removal of any Directors, the remaining Directors of the Company have the sole and exclusive power to fill those vacancies.

The Proxy Organizer proposes to amend the Bylaws of the Company (the "Bylaws") to allow a majority of the Stockholders to fill vacancies on the Board of Directors resulting from the removal of any Directors. The new Bylaw provision will read as follows:

3.3 Vacancies. Vacancies and newly created directorships resulting from any increase in the authorized number of directors elected by the stockholders having the right to vote as a single class may be filled by a majority of the shareholders. Whenever the holders of any class or classes of stock or series thereof are entitled to elect one or more directors by the provisions of the certificate of incorporation, vacancies and newly created directorships of such class or classes or series may be filled by a majority of the shareholders. The directors so chosen shall hold office until the next annual election of the each director's respective class or until their successors are duly elected and shall qualify, unless sooner replaced.

This new bylaw provision will allow a majority of the Stockholders to fill vacancies on the Board of Directors resulting from the removal of any Directors both for the purposes of this proxy as well as in the future. The Proxy Organizer believes this new provision gives the Stockholders more power to vote on the members of the Board of Directors of the Company. The Proxy Organizer intends to vote, and recommends that you vote, for this proposal.

#### PROPOSAL #2 – SECOND AMENDMENT TO THE BYLAWS

The Company's Bylaws currently contain this provision:

3.2 Number. Election and Term of Office . The number of the directors of the Corporation shall not be fewer than three (3) nor more than seven (7), until changed by amendment of the certificate of incorporation or by a bylaw amending this Paragraph 3.2 duly adopted by the vote or written consent of holders of a majority of the outstanding shares entitled to vote. The exact number of directors shall be fixed from time to time, within the limits specified in the certificate of incorporation or in this Section 3.2, by a bylaw or amendment thereof duly adopted by the affirmative vote of the majority of the shares present in person or represented by proxy at a duly held meeting and entitled to vote thereon or by approval of the majority of the shares entitled to vote, or by approval of the board of directors. The directors shall be elected at the annual meeting of the stockholders, except as provided in Paragraph 3.3 of this Article, and each director elected shall hold office until his successor is duly elected and qualified; provided, however, that if the directors shall be divided into classes, each director elected shall hold office until the next election of the class for which such director has been elected, and until his successor has been duly elected and qualified.

The Proxy Organizer proposes to amend the Bylaws of the Company (the "Bylaws") to increase the Company's Board of Directors to 11 Directors. The Nominees will become the Directors for the four newly created Director positions. The new Bylaw provision will read as follows:

3.2 Number. Election and Term of Office. The number of directors of the Corporation shall not be fewer than three (3) nor more than eleven (11), until changed by amendment of the certificate of incorporation or by a bylaw amending this Paragraph 3.2 duly adopted by the vote or written consent of holders of a majority of the outstanding shares entitled to vote. The exact number of directors shall be fixed from time to time, within the limits specified in the certificate of incorporation or in this Section 3.2, by a bylaw or amendment thereof duly adopted by the affirmative vote of the majority of the shares present in person or represented by proxy at a duly held meeting and entitled to vote thereon or by approval of the majority of the shares entitled to vote, or by approval of the board of directors. The directors shall be elected at the annual meeting of the stockholders, except as provided in Paragraph 3.3 of this Article, and each director elected shall hold office until his successor is duly elected and qualified; provided, however, that if the directors shall be divided into classes, each director elected shall hold office until the next election of the class for which such director has been elected, and until his successor has been duly elected and qualified.

This new bylaw provision will allow a majority of the Stockholders to fill the newly created seats on the Board of Directors for the purposes of this proxy as well as in the future. The Proxy Organizer believes this new provision gives the Stockholders more power to vote on the members of the Board of Directors of the Company. The Proxy Organizer intends to vote, and recommends that you vote, for this proposal.

#### PROPOSAL #3 – REMOVAL OF DIRECTORS

The Proxy Organizer proposes to remove Lon E. Otremba, Beverly A. Huss, and Robert B. Shermano as Directors of the Company under Delaware Corporations Law §141(k)(1) for cause.

Delaware General Corporation Law §141(k)(1) reads as follows:

- (k) Any director or the entire board of directors may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors, except as follows:
- (1) Unless the certificate of incorporation otherwise provides, in the case of a corporation whose board is classified as provided in subsection (d) of this section, shareholders may effect such removal only for cause.

The Company's Board is classified as provided in subsection (d) of Delaware General Corporation Law §141(k)(1) and, therefore, Directors may be removed only for cause.

A "for cause" removal of a director requires that the individual be given: (i) specific charges for his removal, (ii) adequate notice, and (iii) a full opportunity to meet the accusation.

The Proxy Organizer believes that these three Directors should be removed for cause because of their breach of fiduciary duty, breach of duty of loyalty, and waste of corporate assets as described in "What Went Wrong with Artes Medical?". The Directors have received adequate notice through this Proxy Statement. Further, each Director has the opportunity to meet the accusation at the Annual Meeting.

The Proxy Organizer believes this proposal is in the best interests of the Stockholders as the Stockholders will then be able to replace the existing Directors of the Company. Therefore, the Proxy Organizer intends to vote, and recommends that you vote, for this proposal.

#### PROPOSAL #4 - FILL VACANCIES LEFT BY THE REMOVAL OF DIRECTORS

The Proxy Organizer proposes to elect four new Directors of the Company to fill the vacancies created by the increase of the number of directorships to 11 pursuant to proposal #2 of this Proxy Statement. The Proxy Organizer proposes to elect Terry Knapp, M.D., Barry Vogel, Eric Donsky, and Dr. Johan Brahme to fill the vacancies created by the increase to the number Directors of the Company.

The Proxy Organizer believes these four Director nominees are qualified to serve on the Company's Board of Directors pursuant to their experience described in their biographies in Proposal #5 below.

Each Nominee, if elected, would hold office until the next annual meeting of shareholders for their respective class or until a successor has been elected and qualified. Although the Proxy Organizer does not anticipate that any of the persons named below will be unable or unwilling to stand for election, in the event of such occurrence, proxies may be voted for a substitute designated by the Proxy Organizer. To the extent current members of the Board of Directors do not agree to serve with the Proxy Organizer's Nominees if the campaign is successful, any vacancies on the Company's Board of Directors created by resignation of such directors are likely to remain vacant. The Proxy Organizer currently has no intention to fill any such vacancies. See Appendix I for additional information about the Nominees, including their ownership, purchase and sale of securities issued by the Company.

The Proxy Organizer intends to vote, and recommends that you vote, for this proposal.

#### PROPOSAL #5 - ELECTION OF DIRECTORS

According to the Company's proxy statement prepared in connection with the 2007 Annual Meeting of the Company, as filed with the SEC on April 30, 2007 (the "Company's Proxy Statement"), the Company currently has seven Directors, of which the terms of the Class II Directors will expire at the Annual Meeting of the Stockholders. Christopher J. Reinhard and John R. Costantino are both Class II Directors for the Company and their terms will expire at this Annual Meeting. The Proxy Organizer proposes that the Stockholders elect Robert Binkele and Charles A. Schliebs to fill the vacancies of the Class II Directors. The Proxy Organizer believes these two Director nominees are qualified to serve on the Company's Board of Directors pursuant to their experience described in their biographies below.

Each Nominee, if elected, would hold office until the next annual meeting of shareholders for their respective class or until a successor has been elected and qualified. Although the Proxy Organizer does not anticipate that any of the persons named below will be unable or unwilling to stand for election, in the event of such occurrence, proxies may be voted for a substitute designated by the Proxy Organizer. To the extent current members of the Board of Directors do not agree to serve with the Proxy Organizer's Nominees if the campaign is successful, any vacancies on the Company's Board of Directors created by resignation of such directors are likely to remain vacant. The Proxy Organizer has no plan to fill any such vacancies. See Appendix I for additional information about the Nominees, including their ownership, purchase and sale of securities issued by the Company.

If elected, the Nominees intend to remove the current Chief Financial Officer of the Company and to appoint William Kachioff as the new Chief Financial Officer of the Company. Background information about Mr. Kachioff is set forth below.

CHARLES A. SCHLIEBS - Mr. Schliebs is the co-founder and Managing Director of iNetworks Advisors, Inc., iNetworks BioOpportunity Fund, LP, and iNetworks Private Fund, LP. iNetworks is a venture capital/private equity group investing primarily in healthcare/life science ventures in North America. Prior to co-founding iNetworks, Mr. Schliebs was a partner from 1988 through 1999 with Jones Day, a 2,300-lawyer, international law firm, where he directed the firm's life sciences practice group worldwide. Mr. Schliebs' substantive expertise was as a securities/corporate finance partner and international business law specialist, and his industry specialization was healthcare/life sciences, counseling primarily multinational healthcare/life science companies. While at Jones Day, Mr. Schliebs was the lawyer responsible for all client service worldwide to Bayer AG, the international pharmaceutical and chemical conglomerate. Prior to joining Jones Day, Mr. Schliebs served in a variety of executive positions at New York Stock Exchange companies such as Hospital Corporation of America ("HCA"), where he co-founded HCA Venture Capital, the company's in-house venture arm, investing in emerging healthcare companies. Over a 24 year legal career, Mr. Schliebs represented a wide variety of healthcare, pharmaceutical, medical device, diagnostic and laboratory/scientific companies.

After concluding his legal career, Mr. Schliebs joined the board of directors of Sunquest Information Systems, Inc., a NASDAQ listed Tucson, Arizona based healthcare information systems company. In his board role, he oversaw the sale of the company to Misys plc for three times the price of the company's stock at the time he was asked to join the board. In addition to serving on the boards of for-profit companies in fields ranging from cardiovascular devices to medical simulation to healthcare IT, he serves on a variety of boards involving entrepreneurship and social issues, including Chatham University's Center for Women's Entrepreneurship, Pittsburgh's Institute for Cross-Cultural Ethics, and the President's Visiting Committee on Social Justice at West Virginia University.

Mr. Schliebs received his J.D. from the Vanderbilt University School of Law, and holds two undergraduate degrees from the University of Pennsylvania, a B.A. and a B.S. in Economics from the Wharton School.

TERRY KNAPP, M.D. - While in Plastic Surgery specialty training at Stanford University, Dr. Knapp developed and patented the enabling technology for Collagen Corporation, which he co-founded in 1975. While serving as Collagen Corporation's first VP of Regulatory and Clinical Affairs, he developed the clinical and regulatory strategies that resulted in the first U.S. product approval by the FDA of a Class III medical device under the Medical Device Act of 1976.

Dr. Knapp currently serves as Chairman of the Board of VisioNetx, Inc., a private spin-off from AcuNetx in the field of human impairment testing. Dr. Knapp also has co-founded, and serves as President of the DRL Foundation, Inc., a not-for-profit foundation providing reconstructive surgery and telehealth to developing nations.

Dr. Knapp served as a Director of Collagen Corporation from 1990 through 1996. Dr. Knapp joined Collagen Corporation and A/W Company of Washington University, St. Louis, in co-founding LipoMatrix, Inc., in 1992 to provide a rationally designed, safe breast implant for women. From 1992 through 1995, Dr. Knapp served as Chairman, President and CEO of LipoMatrix. Dr. Knapp established LipoMatrix in both the U.S.A. and in Neuchâtel, Switzerland, where he built the entire corporate infrastructure. In 1995, LipoMatrix achieved distinction as the first ISO9001 certified breast implant company in the world. While with LipoMatrix, Dr. Knapp invented the method of tagging medical devices with small passive RFID transponders to provide long-term non-invasive device identification. Dr. Knapp serves as a founding member of the Board to the Bard Center for Entrepreneurship Development at the University of Colorado, Denver. He recently served on the Advisory Board for the Governor's Office of Life Sciences and Biotechnology, a component of the Colorado Office of Innovation and Technology. Dr. Knapp also served as a Director of Image Guided Technology, Inc. (NASDAQ: IGTI) until its sale to Stryker Corporation. As founder, Chairman and CEO of PrivaComp, Inc., Dr. Knapp was a finalist for Ernst & Young's 2002 Entrepreneur of the Year in the Rocky Mountain region. Dr. Knapp served as Chief Executive Officer of AcuNetx, Inc., a publicly traded, diverse medical device and information technology company with unique products in the fields of eye movement capture and analysis, occupational safety, and osteoplastic surgery and distraction osteogenesis.

During 17 years of reconstructive plastic surgery practice, Dr. Knapp established two craniofacial anomalies panels, established and managed a nationally accredited and Medicare certified outpatient surgery center, and served the community in numerous capacities. Dr. Knapp has been a volunteer surgeon for Interplast, Inc. on 35 trips to developing nations to provide reconstructive surgery for children. Dr. Knapp founded Vector Health Programs, a community nonprofit, in 1979, and it rapidly became the 13th Medicare accredited hand and upper extremity rehabilitation center in the U.S.

Dr. Knapp has authored numerous scientific articles, book chapters and op-ed pieces for medical journals, and more than fifteen issued and several pending U.S. and foreign patents, most of them relating to transponder usage for patient-based global medical informatics systems, Internet-based medical communications channels, and for implantable bio-sensor RFID transponder-based data acquisition for physiologic parameter monitoring.

In 1970, Dr. Knapp completed his MD degree at University of Florida. In 1998, Dr. Knapp became the eighteenth graduate in the history of the University of Florida College of Medicine to be inducted into its Wall of Fame "for noteworthy contributions to medicine, education and to the benefit of the medical consumer."

ROBERT BINKELE – Mr. Binkele, is the founder and CEO of the Estate Planning Team, Inc. Estate Planning Team, Inc. has grown to service over 2,200 securities advisors, CPAs, attorneys and other professionals nationwide with tax deferral, estate, and pension planning for their clients. Mr. Binkele is also a branch manager and investment advisor for J.P. Turner & Co., LLC. Prior to J.P. Turner & Co, LLC, Mr. Binkele was a branch manager with Brookstreet Securities Corporation. Prior to Brookstreet Securities Corporation, Mr. Binkele was a top wealth manager at Raymond James Financial Services, Inc., he was a member of the Raymond James President's Council and a member of the US Allianz Chairman's Council.

Mr. Binkele earned his Bachelor of Science degree with a major in FCS finance from the University of Utah where he was honored as an Academic All American. He currently serves as the President of the Palm Springs Chapter of the University of Utah Alumni Association.

BARRY VOGEL - In 1997, Mr. Vogel became the President of Canderm, Inc. and vastly increased sales and profitability by restructuring the company. Under his leadership, Canderm has evolved into the leading privately held skin care company in Canada. In 1998, Artecoll®, the predecessor to ArteFill, was approved in Canada as the first and only permanent injectable wrinkle filler. Mr. Vogel personally oversaw Artecoll's market introduction and market development using efficient marketing techniques and extensive hands-on physician training. Mr. Vogel has established Canada as the leading market for Artecoll®/ArteSense® worldwide since its market introduction. Mr. Vogel is considered a leading marketing expert in the dermal filler industry, having thoroughly researched numerous fillers available throughout the world and distributing a unique and complete portfolio comprising a temporary, semi-permanent and permanent filler (Artecoll/ArteSense).

Barry graduated from Western Ivey Business School in London, Ontario with an HBA (Honors Business Administration) in 1979.

ERIC DONSKY – Mr. Donsky has 15 years experience in building biotechnology and life science companies as a founder and senior manager. Mr. Donsky is the CEO of OcuSense, Inc., an in-vitro diagnostics company commercializing novel, laboratory-on-a-card technologies that enable eye care practitioners to quantitatively measure biomarkers in tears at the point-of-care so physicians can personalize treatment and objectively track patient outcomes. The Company's TearLab<sup>TM</sup> product platform is the first and only system of its kind in the eye care markets. OcuSense is a subsidiary of a public company trading on NASDAQ and TSX and is also certified under ISO 13485. Mr. Donsky also founded Molecular BioSciences ("MBI"). MBI developed a cardiovascular device that was licensed to Medtronic. Mr. Donsky was the founding CEO of Zolaris BioSciences, Inc., an early-stage biotechnology company focused on the discovery and development of therapeutics for the treatment of rheumatoid arthritis, multiple sclerosis, and infectious diseases. Prior to founding Zolaris, Mr. Donsky was the founding CEO of Applied CarboChemicals, Inc. ("ACC"), an industrial biotechnology company that pioneered the production of chemicals and plastics from renewable resources. ACC has developed the only process capable of economically manufacturing succinic acid through fermentation.

Mr. Donsky graduated from Boston University in 1987 with a B.S. in Business Administration.

Johan Brahme, M.D. – Dr. Johan Brahme is a board certified Plastic Surgeon and member of the American Society for Plastic Surgery (ASPS). He works in La Jolla, California and is a partner at the La Jolla Cosmetic Surgery Center. Dr. Brahme was among the first U.S. surgeons to incorporate Artefill in his practice and has become an enthusiastic supporter of the product, as well as a longtime shareholder in Artes Medical.

Dr. Brahme and his colleagues are in the process of establishing their La Jolla Cosmetic Surgery Center as the leading 'Center of Excellence' for hands-on, peer-to-peer ArteFill injection training as well as organizing practice development seminars regarding the use of injectable wrinkle treatments and other minimal invasive skin rejuvenation procedures.

Dr. Brahme has extensive experience with the clinical use of ArteFill, both in cosmetic and reconstructive applications. Dr Brahme is an innovator and has lectured on the use of ArteFill and its various potential applications on many occasions, both nationally and internationally. He will be instrumental in providing valuable feedback to the Company as to product performance, market perception and training/marketing strategies.

Dr. Brahme received his surgical training at the UCSD School of Medicine and graduated with honors from both the general surgery and plastic surgery program in. Dr. Brahme has an extensive research background and has published in leading peer reviewed medical journals. Dr. Brahme has also been an active participant in the international surgical relief programs Interface and Fresh Start.

Dr. Brahme is an Associate Clinical Professor of Surgery at UC San Diego School of Medicine and is the past President of the San Diego Plastic Surgery Society.

WILLIAM KACHIOFF (Proposed Chief Financial Officer) – Mr. Kachioff is currently a partner of Tatum, LLC, a national executive services firm focused on the office of the Chief Financial Officer. Mr. Kachioff has 18 years of experience with extensive operational, financial and management experience. Mr. Kachioff is the acting Chief Financial Officer at Clarient, Inc. From 2002 through 2006, Mr. Kachioff was the Chief Financial Officer of Microislet, Inc. From 1998 through 2001, Mr. Kachioff was the Chief Financial Officer of Cutera, Inc. Mr. Kachioff has experience in all aspects of financial management, SEC reporting, accounting, legal affairs, treasury, and investor relations for early-stage to mature life science businesses. Mr. Kachioff has completed a wide variety of financing transactions of approximately \$100 million. Mr. Kachioff built and managed responsive finance operations teams and systems for both public and private companies.

The Proxy Organizer intends to vote, and recommends that you vote, for this proposal.

#### PROPOSAL #6 – PROPOSED FINANCING

The Proxy Organizer's Nominees realize that the Company needs to raise additional operating capital to proceed with its objectives for the near future. The Company recently received a notice from The NASDAQ Stock Market ("NASDAQ") indicating that its stockholders' equity at June 30, 2008 was less than the \$10 million in stockholders' equity required for continued listing on the NASDAQ Global Market. The Nominees' plan for the Company's success in the near future is to complete one or more financing transactions as soon as practical to raise sufficient funds to implement the Nominees plans to turn the Company around as described earlier in this Proxy Statement.

Accordingly, the Nominees propose that the Company sell up to \$20,000,000 of its securities to investors from time to time pursuant to one or more financing transactions occurring (the "Financing"). The Company might issue common stock, warrants to purchase common stock or a new series of preferred stock, or a combination of any of these securities, all as determined by the Nominees.

NASDAQ requires the Company to obtain approval from its stockholders for any financing or series of related financing transactions in which the Company issues 20% or more of its outstanding common stock. Obtaining stockholder approval of the Financing will facilitate the Company's efforts to raise funds in a timely manner to allow the Company to raise the funds necessary to support its future operations and turn around plan. NASDAQ also requires shareholder approval if the financings result in a "change of control" under NASDAQ's rules.

THE PROXY ORGANIZER INTENDS TO VOTE, AND RECOMMENDS THAT YOU VOTE, FOR THIS PROPOSAL.

#### INFORMATION REGARDING ALL NOMINEES

All transactions in securities of the Company engaged in by any Nominee during the past two years, as well as current ownership of any such securities by any Nominee, are listed on Appendix I. No Nominee is a beneficial owner of shares of common stock of the Company. In addition, and except as stated herein, no Nominee or any of their associates has any agreement or understanding with respect to future employment by the Company, and no such person has any agreement or understanding with respect to any future transactions to which the Company will or may be a party.

Except as described herein, no Nominee nor any of their associates (i) has engaged in or had a direct or indirect interest in any transaction or series of transactions since the beginning of the Company's last fiscal year or in any currently proposed transaction, to which the Company or any of its subsidiaries is a party, (ii) owns beneficially or of record any securities of the Company, (iii) borrowed any funds for the purpose of acquiring or holding any securities of the Company or is presently, or has been within the past year, a party to any contract, arrangement or understanding, with any person with respect to securities of the Company.

#### AGREEMENTS WITH NOMINEES

The Proxy Organizer is entering into letter agreements (the "Nominee Agreements") with each of the Nominees with respect to their service as Nominees, to stand for election as Directors of the Company at the Annual Meeting. The Nominee Agreements each provide, among other things, as follows:

- The Nominee acknowledges that he has agreed to become a member of the slate of Nominees to stand for election as Directors of the Company in connection with a proxy contest with management of the Company in respect of the election of Directors of the Company at the Annual Meeting;
  - The Proxy Organizer agrees to pay the costs of the proxy contest; and
- The Nominee agrees to withdraw as a Nominee of the Proxy Organizer if requested to do so by the Proxy Organizer at any time prior his election as a Director of the Company.

#### OTHER MATTERS TO BE CONSIDERED AT THE ANNUAL MEETING

Except as set forth above, the Proxy Organizer is not aware of any other proposals to be brought before the Annual Meeting. Should other proposals be brought before the Annual Meeting, the persons named on the blue proxy card will abstain from voting on such proposals unless such proposals adversely affect the interests of the Proxy Organizer and/or the Nominees as determined by the Proxy Organizer in its sole discretion, in which event such persons will vote on such proposals at their discretion.

#### **VOTING PROCEDURES**

Only Stockholders of record as of the Record Date are entitled to notice of and to vote at the Annual Meeting or any adjournments thereof. On March 31, 2008, there were 16,514,163 shares of Common Stock outstanding. Each share of Common Stock is entitled to one vote on the matters to be presented at the Annual Meeting.

A majority of the shares outstanding must be present in person or by proxy to constitute a quorum at the Annual Meeting. If a share is represented for any purpose at the Annual Meeting, it is deemed to be present for all other matters. Abstentions and broker non-votes will be counted for purposes of determining the presence or absence of a quorum. "Broker Non-votes" are shares held by brokers or nominees which are present in person or represented by proxy, but which are not voted on a particular matter because instructions have not been received from the beneficial owner. Under applicable Delaware law, the effect of broker nonvotes on a particular matter depends on whether the matter is one as to which the broker or nominee has discretionary voting authority. The effect of broker nonvotes on the specific items to be brought before the Annual Meeting is discussed under each item.

According to the Delaware General Corporation Law, directors are elected by a plurality of the votes cast by the holders of Company's Common Stock at a meeting at which a quorum is present, when the bylaws of the Company do not state otherwise. Plurality means that the number of votes cast for a director in a contest of two or more directors that is greater than the number cast for any other candidate but not more than half the total votes cast.

According to the bylaws of the Company and applicable law, removal of a director and amendments to the bylaws of the Company require a majority vote of the current outstanding shares of the Company.

#### PROXY PROCEDURES

IN ORDER FOR YOUR VIEWS TO BE REPRESENTED AT THE ANNUAL MEETING, PLEASE MARK, SIGN, DATE AND RETURN THE ENCLOSED BLUE PROXY CARD AND RETURN IT TO PROXY ORGANIZER C/O MACKENZIE PARTNERS, INC. IN THE ENCLOSED POSTAGE-PREPAID ENVELOPE.

The accompanying blue proxy card will be voted at the Annual Meeting in accordance with your instructions on such card.

Any proxy may be revoked at any time prior to the time a vote is taken by delivering to the Secretary of the Company a notice of revocation bearing a later date, by a duly executed proxy bearing a later date or by attending the Annual Meeting and voting in person.

Only holders of record as of the close of business on the Record Date will be entitled to vote. If you were a Stockholder of record on the Record Date, you will retain your voting rights of the Annual Meeting even if you sell such shares after the Record Date. Accordingly, it is important that you vote the shares held by you on the Record Date, or grant a proxy to vote such shares on the blue proxy card, even if you sell such shares after the Record Date.

#### SOLICITATION OF PROXIES

Solicitation of proxies shall be made only by the Proxy Organizer.

The Proxy Organizer has retained MacKenzie Partners, Inc. (the "Solicitor") to conduct the solicitation, for which the Solicitor is to receive a fee of approximately \$75,000, plus reimbursement for its reasonable out-of-pocket expenses. The Proxy Organizer has agreed to indemnify the Solicitor against certain liabilities and expenses, including liabilities under federal securities laws. Proxies may be solicited by mail, courier services, advertising, telephone, telecopier, e-mail or in person. It is anticipated that the Solicitor will employ approximately 25 persons to solicit Stockholders for the Annual Meeting.

Costs related to the solicitation of proxies, including expenditures for attorneys, accountants, public relations and financial advisers, proxy solicitors, payments to nominees, advertising, printing, transportation and related expenses and filing fees, will be borne by the Proxy Organizer. Such costs are expected to be approximately \$250,000 in total. The Proxy Organizer intends to seek reimbursement for the costs and expenses associated with the proxy solicitation in the event that the Nominees are elected to the Board of Directors of the Company, but does not intend to submit the issue of reimbursement to a vote of security holders.

#### CERTAIN INFORMATION REGARDING PROXY ORGANIZER

On June 30, 2008, the Proxy Organizer determined that he was not satisfied with current management of the Company and decided to explore available options to maximize stockholder value. The business address of the Proxy Organizer is 19 Burning Tree Road, Newport Beach, CA 92660.

All transactions in the securities of the Company effected within the past two years by Proxy Organizer will be contained in Appendix I.

The Proxy Organizer assumes no responsibility for the accuracy or completeness of any information contained herein which is based on, or incorporated by reference to, the Company's Proxy Statement.

#### CONCLUSION

If Proposal #1, amendment of the Bylaws of the Company to allow a majority of the Stockholders to fill vacancies or newly created directorships on the Board of Directors, is not passed, Proposals #2, #3, and #4 will become moot as the Stockholders will not be able to fill vacancies on the Board of Directors. However, even if Proposal #1 is not successful, Proposals #5 and #6 will still be effective as two Class II Directors' terms are expiring and the Proxy Organizer seeks to elect two new Nominees to these Board seats and the Company will need to sell up to \$20,000,000 of its securities to investors from time to time pursuant to one or more financing transactions to continue its operations.

THE PROXY ORGANIZER STRONGLY URGES YOU TO VOTE FOR THE TWO AMENDMENTS TO THE BYLAWS, REMOVAL OF THREE OF THE CURRENT BOARD OF DIRECTORS OF THE COMPANY, THE ELECTION OF THE NOMINEES, AND THE PROPOSED FINANCING BY SIGNING, DATING AND RETURNING THE ENCLOSED PROXY IN THE POSTAGE-PAID ENVELOPE PROVIDED TO YOU WITH THIS PROXY STATEMENT. IF YOU HAVE SIGNED THE BLUE PROXY CARD AND NO MARKING IS MADE ON IT, YOU WILL BE DEEMED TO HAVE GIVEN A DIRECTION TO VOTE THE SHARES REPRESENTED BY THE BLUE PROXY CARD FOR THE AMENDMENTS TO THE BYLAWS, THE REMOVAL OF THREE OF THE CURRENT BOARD OF DIRECTORS OF THE COMPANY, AND FOR THE ELECTION OF ALL OF THE NOMINEES.

PROXY ORGANIZER

Dr. H. Michael Shack Date: September 16, 2008

#### **IMPORTANT**

- 1. If your shares are held in your own name, please mark, date and mail the enclosed blue proxy card to the Proxy Organizer, in the postage-paid envelope provided.
- 2. If your shares are held in the name of a brokerage firm, bank nominee or other institution, only it can vote such shares and only upon receipt of your specific instructions. Accordingly, you should contact the person responsible for your account and give instructions for a blue proxy card to be signed representing your shares.

ONLY YOUR LATEST DATED PROXY FOR THE ANNUAL MEETING WILL COUNT AT THE ANNUAL MEETING.

If you have questions or need assistance voting your shares please contact:

105 Madison Avenue New York, New York 10016 proxy@mackenziepartners.com Call Collect: (212) 929-5500 or Toll-Free (800) 322-2885

# APPENDIX I

# SUPPLEMENTAL NOMINEE AND OTHER INFORMATION

Set forth below is (a) the name and business address of each of the Nominees in the solicitation made pursuant to this Proxy Statement, and (b) the dates, types and amounts of each Nominee's purchases and sales of the Company's debt and equity securities within the past two years.

			Number of	
Name and Business	Transaction	Number of Securities	Securities	Current
Address	Date	Purchased	Sold	Ownership
Dr. H. Michael Shack	1/10/2007	2,500		2,500
19 Burning Tree Road	1/10/2007	500		3,000
Newport Beach,				
CA 92660	1/10/2007	2,000		5,000
	1/10/2007	2,500		7,500
	1/10/2007	500		8,000
	1/10/2007	2,000		10,000
	1/11/2007	300		10,300
	1/11/2007	700		11,000
	1/11/2007	300		11,300
	1/11/2007	200		11,500
	1/11/2007	600		12,100
	1/11/2007		1,000	11,100
	1/11/2007		1,500	9,600
	1/11/2007	300		9,900
	1/11/2007	700		10,600
	1/11/2007	300		10,900
	1/17/2007			10,900
	1/17/2007	1,000		11,900
	1/17/2007		1,500	10,400
	1/17/2007		1,600	8,800
	1/17/2007		1,500	7,300
	1/18/2007	1,000		8,300
	1/19/2007	1,000		9,300
	1/19/2007	1,000		10,300
	1/19/2007	1,000		11,300
	1/19/2007	500		11,800
	1/19/2007	500		12,300
	1/19/2007	1,000		13,300
	1/19/2007		500	12,800
	1/19/2007		500	12,300
	1/19/2007		1,000	11,300
	1/19/2007		200	11,100
	1/22/2007		1,000	10,100
	1/22/2007	700		10,800
	1/22/2007	500		11,300
	1/23/2007		1,500	9,800

Edgar Filing: Shack Herbert Michael - Form PRRN14A

1/23/2007		1,000	8,800
1/23/2007		1,500	7,300
1/24/2007	1,000		8,300
1/24/2007	100		8,400
1/24/2007	900		9,300
1/24/2007	1,000		10,300
1/24/2007		1,000	9,300
1/25/2007	100		9,400
1/25/2007	250		9,650
1/25/2007	100		9,750
1/25/2007	150		9,900
1/25/2007	200		10,100

1/25/2007	450		10,550
1/26/2007		100	10,450
1/26/2007		100	10,350
1/26/2007		100	10,250
1/26/2007		100	10,150
1/26/2007		100	10,050
1/26/2007		100	9,950
1/26/2007		100	9,850
1/26/2007		100	9,750
1/26/2007		250	9,500
1/26/2007		400	9,100
1/26/2007	200		9,300
2/1/2007		50	9,250
2/1/2007		400	8,850
2/1/2007		550	8,300
2/1/2007		1,000	7,300
2/1/2007	200		7,500
2/1/2007	550		8,050
2/1/2007		750	7,300
2/2/2007	800		8,100
2/2/2007	200		8,300
2/2/2007	1,500		9,800
2/2/2007	500		10,300
2/2/2007		1,000	9,300
2/2/2007	875	,	10,175
2/6/2007	750		10,925
2/8/2007	1,000		11,925
2/12/2007	1,500		13,425
2/12/2007	1,000		14,425
2/12/2007	1,000		15,425
2/12/2007	1,500		16,925
2/12/2007	675		17,600
2/12/2007	1,000		18,600
2/12/2007	1,000		19,600
2/12/2007	500		20,100
2/12/2007	800		20,900
2/13/2007	1,000		21,900
2/13/2007	400		22,300
2/13/2007	1,000		23,300
2/13/2007	1,000		24,300
2/13/2007	1,000		25,300
2/13/2007	1,000		26,300
2/13/2007	1,000		27,300
2/13/2007	1,000		28,300
2/13/2007	1,000		29,300
2/15/2007	1,000		30,300
2/15/2007	1,000		31,300
2/15/2007	1,000	180	31,120
2/16/2007		1,820	29,300
211012007		1,020	27,500

2/16/2007	100		29,400
2/16/2007	900		30,300
2/16/2007	1,000		31,300
2/16/2007	350		31,650
2/16/2007	200		31,850
2/16/2007	50		31,900
2/20/2007	25		31,925
2/20/2007	100		32,025
2/20/2007	100		32,125
2/20/2007	100		32,225
2/20/2007	1,675		33,900
2/20/2007	1,000		34,900
2/20/2007	1,000		35,900
2/20/2007	2,000		37,900
2/20/2007		1,000	36,900
2/20/2007		1,000	35,900
2/20/2007		1,000	34,900
2/20/2007		2,000	32,900
2/20/2007		2,000	30,900
2/21/2007	100	,	31,000
2/21/2007	1,500		32,500
2/21/2007	900		33,400
2/21/2007	100		33,500
2/21/2007	1,400		34,900
2/21/2007	1,100	1,000	33,900
2/22/2007	500	1,000	34,400
2/22/2007	1,500		35,900
2/22/2007	500		36,400
2/22/2007	400		36,800
2/22/2007	100		36,900
2/22/2007	100	1,500	35,400
2/22/2007		1,000	34,400
2/22/2007		1,000	33,400
2/22/2007		1,000	32,400
2/22/2007		200	32,200
2/22/2007		1,795	30,405
2/23/2007	1,800	1,773	32,205
2/23/2007	700		32,905
2/23/2007	465		33,370
2/23/2007	100		33,470
2/23/2007	1,935		35,405
2/23/2007	500		35,905
2/23/2007	1,000		36,905
2/23/2007	1,000		30,903 37,005
2/23/2007	400		37,003 37,405
2/23/2007	500		
2/23/2007	300	600	37,905 37,305
			37,305 37,305
2/23/2007		100	37,205

2/23/2007 300 36,905

	100	36,805
	•	35,805
	1,000	34,805
		34,905
		35,005
		35,105
100		35,205
100		35,305
400		35,705
300		36,005
200		36,205
	3,600	32,605
	1,400	31,205
2,000		33,205
1,000		34,205
1,000		35,205
· ·		36,205
		36,705
100		36,805
400		37,205
		37,505
		39,705
-		40,305
		40,495
		40,695
		40,807
		41,107
		42,205
· ·		43,205
		44,705
		45,705
· ·		48,205
		50,705
-		53,205
		53,605
		54,005
		54,105
		54,205
100	1 000	53,205
		51,705
		•
		51,588
		50,588
		48,088
		45,588
240	2,8/3	42,715
		42,955
		43,455
60		43,515
	100 400 300 200 2,000 1,000 1,000 1,000 500	1,000 1,000 100 100 100 100 100 100 100

2/27/2007 3,000 40,515

		2 2 4 7	20.200
2/28/2007		2,215	38,300
2/28/2007		300	38,000
2/28/2007	• 000	200	37,800
3/5/2008	2,000		39,800
3/5/2008	2,000		41,800
3/5/2008	2,000		43,800
3/5/2008	2,000		45,800
3/5/2008	1,000		46,800
3/5/2008	650		47,450
3/5/2008	100		47,550
3/5/2008	300		47,850
3/5/2008	950		48,800
3/5/2008		2,100	46,700
3/5/2008		900	45,800
3/5/2008		2,000	43,800
3/5/2008		1,000	42,800
3/5/2007	100		42,900
3/5/2007	100		43,000
3/5/2007	100		43,100
3/5/2007	1,329		44,429
3/5/2007	100		44,529
3/5/2007	771		45,300
3/5/2007	300		45,600
3/5/2007	200		45,800
3/5/2007	200		46,000
3/5/2007	100		46,100
3/5/2007	100		46,200
3/5/2007	250		46,450
3/5/2007	800		47,250
3/5/2007	350		47,600
3/5/2007	100		47,700
3/5/2007	50		47,750
3/6/2007	550		48,300
3/6/2007	100		48,400
3/6/2007	400		48,800
3/6/2007	400	1,500	47,300
3/6/2007			·
		1,000	46,300
3/6/2007		1,000	45,300
3/6/2007	1 000	2,000	43,300
3/7/2007	1,000		44,300
3/7/2007	700		45,000
3/7/2007	300		45,300
3/7/2007	500		45,800
3/7/2007	1,000		46,800
3/7/2007	1,000		47,800
3/7/2007	700		48,500
3/7/2007	300		48,800
3/7/2007	800		49,600

3/7/2007	100	49.700

3/7/2007	100		49,800
3/7/2007	1,000		50,800
3/7/2007	1,500		52,300
3/7/2007	1,000		53,300
3/7/2007	100		53,400
3/7/2007	100		53,500
3/7/2007	850		54,350
3/7/2007	500		54,850
3/7/2007	200		55,050
3/7/2007	200		55,250
3/7/2007	600		55,850
3/7/2007	100		55,950
3/7/2007	400		56,350
3/7/2007	450		56,800
3/7/2007	100		56,900
3/7/2007	100		57,000
3/7/2007	500		57,500
3/8/2007	2,000		59,500
3/8/2007	1,500		61,000
3/8/2007	1,000		62,000
3/8/2007	400		62,400
3/8/2007	289		62,689
3/8/2007	311		63,000
3/8/2007	100		63,100
3/8/2007	100		63,200
3/8/2007	100		63,300
3/8/2007	100		63,400
3/9/2007	2,500		65,900
3/9/2007	1,500		67,400
3/9/2007	500		67,900
3/9/2007	1,000		68,900
3/9/2007		2,500	66,400
3/9/2007		1,000	65,400
3/9/2007		300	65,100
3/9/2007		300	64,800
3/9/2007		100	64,700
3/9/2007		100	64,600
3/9/2007		100	64,500
3/9/2007		100	64,400
3/9/2007		500	63,900
3/9/2007		1,600	62,300
3/9/2007	250		62,550
3/12/2007	600		63,150
3/12/2007	900		64,050
3/12/2007	1,000		65,050
3/12/2007	•	1,150	63,900
3/12/2007		1,100	62,800
3/12/2007		300	62,500
			•

3/12/2007 300 62,800

3/13/2007		120	62,680
3/13/2007		200	62,480
3/13/2007	100		62,580
3/13/2007	53		62,633
3/13/2007	47		62,680
3/13/2007	53		62,733
3/13/2007	47		62,780
3/13/2007	100		62,880
3/13/2007	100		62,980
3/13/2007	100		63,080
3/13/2007	100		63,180
3/13/2007	100		63,280
3/13/2007	100		63,380
3/13/2007	100		63,480
3/13/2007	100		63,580
3/13/2007	100		63,680
3/13/2007	800		64,480
3/13/2007	2,000		66,480
3/13/2007	2,000		68,480
3/13/2007	100		68,580
3/13/2007	1,400		69,980
3/13/2007	400		70,380
3/13/2007	71		70,451
3/13/2007	200		70,651
3/13/2007	100		70,751
3/13/2007	229		70,980
3/13/2007	400		71,380
3/14/2007	700		72,080
3/14/2007	, 00	60	72,020
3/14/2007		1,400	70,620
3/14/2007	500	-,	71,120
3/14/2007	100		71,220
3/14/2007	100		71,320
3/14/2007	100		71,420
3/14/2007	100		71,520
3/14/2007	100		71,620
3/15/2007	132		71,752
3/15/2007	1,868		73,620
3/15/2007	1,000	2,500	71,120
3/15/2007	500	2,300	71,620
3/15/2007	1,500		73,120
3/15/2007	1,300	586	73,120
3/15/2007	500	360	
3/15/2007			73,034 74,034
	1,000 800		
3/15/2007			74,834
3/15/2007	50		74,884
3/15/2007	100		74,984
3/15/2007	200		75,184

3/15/2007	500	75,684
311312001	200	75,001

2/15/2007	100		75 704
3/15/2007	100		75,784
3/15/2007	235		76,019
3/15/2007	100	4.000	76,119
3/16/2007		1,000	75,119
3/16/2007		2,000	73,119
3/16/2007		1,100	72,019
3/16/2007		300	71,719
3/16/2007		600	71,119
3/16/2007		1,000	70,119
3/19/2007		900	69,219
3/20/2007		100	69,119
3/20/2007		900	68,219
3/20/2007	600		68,819
3/20/2007	200		69,019
3/20/2007	100		69,119
3/20/2007	100		69,219
3/21/2007		100	69,119
3/21/2007		800	68,319
3/21/2007		100	68,219
3/21/2007		800	67,419
3/21/2007		500	66,919
3/21/2007		1,000	65,919
3/21/2007		1,000	64,919
3/21/2007	300	1,000	65,219
3/21/2007	100		65,319
3/21/2007	300		65,619
3/21/2007	100		65,719
3/21/2007	200		65,919
3/21/2007	200		·
3/21/2007	100		66,119 66,219
			·
3/21/2007	200		66,419
3/21/2007	100		66,519
3/21/2007	100		66,619
3/21/2007	100		66,719
3/21/2007	100		66,819
3/21/2007	65		66,884
3/21/2007	300		67,184
3/21/2007	215		67,399
3/21/2007	1,885		69,284
3/21/2007	100		69,384
3/21/2007	915		70,299
3/21/2007	100		70,399
3/21/2007	100		70,499
3/21/2007	50		70,549
3/21/2007	100		70,649
3/21/2007	750		71,399
3/22/2007	602		72,001
3/22/2007	1,898		73,899

3/22/2007 200 74,099

2/22/2007	200		74 407
3/22/2007	388		74,487
3/22/2007	1,912		76,399
3/22/2007	2,500	600	78,899
3/22/2007		600	78,299
3/22/2007	400	1,900	76,399
3/22/2007	400		76,799
3/22/2007	500		77,299
3/22/2007	1,000		78,299
3/22/2007	602		78,901
3/22/2007	1,898		80,799
3/22/2007	200		80,999
3/22/2007	388		81,387
3/22/2007	1,912		83,299
3/22/2007	2,500		85,799
3/22/2007		600	85,199
3/22/2007		1,900	83,299
3/22/2007	400	,	83,699
3/22/2007	500		84,199
3/22/2007	1,000		85,199
3/22/2007	500		85,699
3/22/2007	500		86,199
3/22/2007	500		86,699
3/22/2007	500		87,199
3/22/2007	200		87,399
3/22/2007	200	100	87,299
3/22/2007		100	87,199
3/22/2007		500	86,699
3/23/2007	1,200	300	87,899
3/23/2007	300		•
3/23/2007			88,199
	200		88,399
3/23/2007	2,300	2.500	90,699
3/23/2007		2,500	88,199
3/23/2007		900	87,299
3/23/2007	4.000	1,400	85,899
3/23/2007	1,200		87,099
3/23/2007	300		87,399
3/23/2007	200		87,599
3/23/2007	2,300		89,899
3/23/2007		2,500	87,399
3/23/2007		900	86,499
3/23/2007		1,400	85,099
3/26/2007		1,000	84,099
3/26/2007		1,100	82,999
3/26/2007	200		83,199
3/26/2007		2,000	81,199
3/26/2007		2,000	79,199
3/26/2007		1,000	78,199
3/26/2007		1,100	77,099
		•	•

3/26/2007 200 76,899

3/26/2007		2,000	74,899
3/26/2007		2,000	72,899
3/26/2007		500	72,399
3/26/2007		500	71,899
3/26/2007		655	71,244
3/26/2007		345	70,899
3/26/2007		1,500	69,399
3/26/2007		1,500	67,899
3/27/2007			67,899
3/27/2007			67,899
3/27/2007		1,600	66,299
3/27/2007		600	65,699
3/27/2007	500		66,199
3/27/2007	100		66,299
3/27/2007	100		66,399
3/28/2007	2,500		68,899
3/28/2007	2,500		71,399
3/28/2007	300		71,699
3/28/2007	200		71,899
3/28/2007	100		71,999
3/28/2007	100		72,099
3/28/2007	100		72,199
3/28/2007	100		72,299
3/28/2007	100		72,399
3/28/2007	200		72,599
3/28/2007	100		72,699
3/28/2007	100		72,799
3/28/2007	600		73,399
3/28/2007	300		73,699
3/28/2007	300	500	73,199
3/28/2007		400	72,799
3/29/2007	1,000	400	73,799
3/29/2007	500		74,299
3/29/2007	400		74,699
3/29/2007	900		75,599
3/29/2007	700		76,299
3/29/2007	1,500		77,799
3/29/2007	1,500	200	77,799
3/29/2007		100	
3/29/2007			77,499
	100	2,400	75,099
3/29/2007	100		75,199 76,100
3/29/2007	1,000		76,199
3/29/2007	500		76,699
3/29/2007	400		77,099
3/29/2007	900		77,999
3/29/2007	700		78,699
3/29/2007	1,500	200	80,199
3/29/2007		200	79,999

3/29/2007	100	79,899
3/29/2007	2,400	77,499
3/29/2007	100	77,399
3/29/2007	500	76,899
3/29/2007	100	76,799
3/29/2007	100	76,699
3/29/2007	100	76,599
3/29/2007	200	76,399
3/29/2007	700	75,699
3/29/2007	100	75,599
3/29/2007	100	75,499
3/29/2007	1,600	73,899
3/29/2007	100	73,799
3/29/2007	2,400	71,399
3/29/2007	2,500	68,899
3/29/2007		66,899
	2,000	•
3/29/2007	100	66,999
3/29/2007	566	67,565
3/29/2007	100	67,665
3/29/2007	400	68,065
3/29/2007	100	68,165
3/29/2007	100	68,265
3/29/2007	100	68,365
3/29/2007	1,000	69,365
3/29/2007	34	69,399
3/29/2007	100	69,499
3/29/2007	400	69,899
3/29/2007	2,000	71,899
3/29/2007	100	71,999
3/29/2007	400	72,399
3/29/2007	100	72,499
3/29/2007	100	72,599
3/29/2007	300	72,899
3/29/2007	100	72,999
3/29/2007	100	73,099
3/29/2007	100	73,199
3/29/2007	100	73,299
3/29/2007	100	73,399
3/29/2007	100	73,499
3/29/2007	100	73,599
3/29/2007	100	
		73,699
3/29/2007	200	73,899
3/29/2007	100	73,999
3/29/2007	400	74,399
3/29/2007	100	74,499
3/29/2007	100	74,599

3/29/2007	50		74,649
3/29/2007	100		74,749
3/29/2007	100		74,849
3/29/2007	300		75,149
3/29/2007	100		75,249
3/29/2007	400		75,649
3/30/2007		400	75,249
3/30/2007		5,600	69,649
3/30/2007		700	68,949
3/30/2007		400	68,549
3/30/2007		5,600	62,949
3/30/2007		700	62,249
4/2/2007	2,000	,	64,249
4/2/2007	2,000		66,249
4/2/2007	2,000		68,249
4/2/2007	2,000		70,249
4/2/2007	200		70,449
4/2/2007	1,127		71,576
4/2/2007	1,127	200	71,376
4/2/2007		2,000	69,376
4/2/2007		2,800	66,576
4/2/2007		2,800 77	66,499
			•
4/2/2007		2,800	63,699
4/2/2007		1,000	62,699
4/2/2007		700	61,999
4/4/2007	1.500	2,000	59,999
4/4/2007	1,500		61,499
4/4/2007	2,500		63,999
4/4/2007	2,000		65,999
4/4/2007	1,500		67,499
4/4/2007		2,000	65,499
4/4/2007	1,500		66,999
4/4/2007	2,500		69,499
4/4/2007	2,000		71,499
4/4/2007	1,500		72,999
4/4/2007		1,900	71,099
4/4/2007		100	70,999
4/4/2007		100	70,899
4/4/2007		100	70,799
4/4/2007		100	70,699
4/4/2007		100	70,599
4/4/2007		100	70,499
4/4/2007		100	70,399
4/4/2007		100	70,299
4/4/2007		100	70,199
4/4/2007		100	70,099
., ., =00,		130	, 0,0,0

4/4/2007		100	69,999
4/5/2007	1,000		70,999
4/5/2007	500		71,499
4/5/2007	1,000		72,499
4/5/2007	100		72,599
4/5/2007	1,900		74,499
4/5/2007		242	74,257
4/5/2007		2,258	71,999
4/5/2007	2,000		73,999
4/5/2007	500		74,499
4/5/2007	600		75,099
4/5/2007	400		75,499
4/5/2007	500		75,999
4/5/2007		2,500	73,499
4/5/2007		800	72,699
4/5/2007		66	72,633
4/5/2007		134	72,499
4/5/2007	1,000		73,499
4/5/2007	500		73,999
4/5/2007	1,000		74,999
4/5/2007	100		75,099
4/5/2007	1,900		76,999
4/5/2007	,	242	76,757
4/5/2007		2,258	74,499
4/5/2007	2,000	,	76,499
4/5/2007	500		76,999
4/5/2007	600		77,599
4/5/2007	400		77,999
4/5/2007	500		78,499
4/5/2007		2,500	75,999
4/5/2007		800	75,199
4/9/2007	300	000	75,499
4/9/2007	1,100		76,599
4/9/2007	100		76,699
4/9/2007	200		76,899
4/9/2007	300		77,199
4/9/2007	300	1,500	75,699
4/10/2007		100	75,599
4/10/2007		3,200	72,399
4/10/2007		1,000	71,399
4/10/2007		200	71,199
4/10/2007		2,000	69,199
4/10/2007		1,778	67,421
4/10/2007		1,778	66,421
4/11/2007		1,122	65,299
4/11/2007		100	65,199

4/12/2007	1,800		66,999
4/12/2007	700		67,699
4/13/2007		2,500	65,199
4/13/2007	1,500		66,699
4/13/2007	1,400		68,099
4/13/2007	·	200	67,899
4/13/2007		1,000	66,899
4/17/2007		700	66,199
4/17/2007		1,000	65,199
4/17/2007		1,000	64,199
4/17/2007	5,000	1,000	69,199
4/17/2007	200		69,399
4/17/2007	800		•
	800	1 000	70,199
4/17/2007	600	1,000	69,199
4/18/2007	600		69,799
4/18/2007	900		70,699
4/18/2007	1,000		71,699
4/18/2007	500		72,199
4/18/2007	500		72,699
4/18/2007	1,000		73,699
4/18/2007	1,200		74,899
4/18/2007	800		75,699
4/18/2007		1,500	74,199
4/18/2007		1,500	72,699
4/18/2007		3,500	69,199
4/18/2007	500		69,699
4/19/2007	1,000		70,699
4/19/2007	200		70,899
4/19/2007	300		71,199
4/19/2007	200		71,399
4/19/2007	100		71,499
4/19/2007	100		71,599
4/19/2007	600		72,199
4/19/2007	000	100	72,099
4/19/2007		1,000	71,099
4/19/2007	1 200	1,000	
	1,200		72,299
4/19/2007	200		72,499
4/19/2007	800		73,299
4/19/2007	200		73,499
4/20/2007	600		74,099
4/20/2007	900		74,999
4/20/2007	1,400		76,399
4/20/2007	600		76,999
4/20/2007	1,000		77,999
4/20/2007	500		78,499
4/20/2007	100		78,599

4/20/2007	100		78,699
4/20/2007	375		79,074
4/20/2007	425		79,499
4/20/2007	900		80,399
4/20/2007	100		80,499
4/20/2007	1,000		81,499
4/20/2007	500		81,999
4/20/2007		4,800	77,199
4/20/2007	2,500		79,699
4/20/2007	1,800		81,499
4/20/2007	700		82,199
4/20/2007	600		82,799
4/20/2007	400		83,199
4/20/2007	100		83,299
4/20/2007	50		83,349
4/20/2007	500		83,849
4/20/2007	100		83,949
4/23/2007	2,100		86,049
4/23/2007	900		86,949
4/23/2007	1,000		87,949
4/23/2007	1,000		88,949
4/23/2007	1,000		89,949
4/23/2007	700		90,649
4/23/2007	800		91,449
4/23/2007	1,000		92,449
4/23/2007	,	3,500	88,949
4/23/2007		3,000	85,949
4/23/2007	400	2,000	86,349
4/23/2007	1,600		87,949
4/23/2007	500		88,449
4/23/2007	300		88,749
4/23/2007	400		89,149
4/23/2007	300		89,449
4/23/2007	200		89,649
4/23/2007	100		89,749
4/23/2007	100		89,849
4/23/2007	250		90,099
4/24/2007	1,000		91,099
4/24/2007	355		91,454
4/24/2007	1,145		92,599
4/24/2007	1,173	3,000	89,599
4/24/2007		10,000	79,599
4/24/2007		750	78,849
4/24/2007	600	750	78,849
4/25/2007	000	1,000	79, <del>44</del> 9 78,449
4/25/2007		3,500	78, <del>44</del> 9 74,949
4/25/2007			•
4/25/2007	100	2,565	72,384
4/23/200/	100		72,484

4/26/2007	200		72,684
4/26/2007	2,000		74,684
4/26/2007	267		74,951
4/26/2007	233		75,184
4/26/2007	200		75,384
4/26/2007	100		75,484
4/27/2007		2,500	72,984
4/27/2007		635	72,349
4/27/2007	2,000		74,349
4/27/2007	200		74,549
4/27/2007	1,000		75,549
4/27/2007	500		76,049
4/27/2007	200		76,249
4/27/2007	100		76,349
4/27/2007	200		76,549
4/27/2007	100		76,649
4/27/2007	400		77,049
4/27/2007	100		77,149
4/27/2007	100		77,249
4/27/2007	100		77,349
4/27/2007	100		77,449
4/27/2007	200		77,649
4/27/2007	800		77,049 78,449
4/27/2007	100		•
			78,549
4/27/2007	200		78,749
4/27/2007	100		78,849
4/27/2007	200		79,049
4/27/2007	100		79,149
4/27/2007	100		79,249
4/27/2007	100		79,349
4/27/2007	200		79,549
4/27/2007	200		79,749
4/27/2007	100		79,849
4/27/2007	100		79,949
4/27/2007	100		80,049
4/27/2007	200		80,249
4/27/2007	100		80,349
4/27/2007	100		80,449
4/27/2007	100		80,549
4/27/2007	200		80,749
4/27/2007	100		80,849
4/27/2007	100		80,949
4/27/2007	100		81,049
4/27/2007	100		81,149
4/27/2007	100		81,249
4/27/2007	100		81,349
4/27/2007	100		81,449
4/27/2007	100		81,549
	100		- <b>,</b> -

4/27/2007 1,000 82,549

4/27/2007	100		82,649
4/27/2007	100		82,749
4/27/2007	1,000		83,749
4/27/2007	300		84,049
4/27/2007	100		84,149
4/27/2007	100		84,249
4/27/2007	10		84,259
4/27/2007	100		84,359
4/27/2007	100		84,459
4/27/2007	100		84,559
4/27/2007	100		84,659
4/30/2007		100	84,559
4/30/2007	2,000		86,559
4/30/2007	2,100		88,659
4/30/2007	900		89,559
4/30/2007	2,000		91,559
4/30/2007	3,000		94,559
4/30/2007	500		95,059
4/30/2007	100		95,159
4/30/2007	150		95,309
5/1/2007	1,200		96,509
5/1/2007	300		96,809
5/1/2007		1,350	95,459
5/1/2007		400	95,059
5/1/2007		610	94,449
5/1/2007		1,500	92,949
5/1/2007	500	,	93,449
5/2/2007		2,500	90,949
5/2/2007		3,000	87,949
5/2/2007		2,500	85,449
5/2/2007		2,500	82,949
5/2/2007		1,500	81,449
5/2/2007	200	-,	81,649
5/2/2007	100		81,749
5/2/2007	163		81,912
5/2/2007	37		81,949
5/2/2007	1,500		83,449
5/2/2007	900		84,349
5/2/2007	100		84,449
5/2/2007	100		84,549
5/2/2007	100		84,649
5/2/2007	800		85,449
5/2/2007	80		85,529
5/2/2007	400		85,929
5/2/2007	20		85,949
5/2/2007	100		86,049
5/2/2007	500		86,549
5/2/2007	400		86,949
31414001	400		00,243

5/2/2007 500 87,449

5/3/2007		2,500	84,949
5/3/2007		500	84,449
5/3/2007		2,100	82,349
5/3/2007	400	,	82,749
5/3/2007	1,100		83,849
5/3/2007	5,000		88,849
5/3/2007	7,500		96,349
5/3/2007	7,500	1,500	94,849
5/3/2007		1,500	93,349
5/3/2007		1,000	92,349
5/3/2007		900	•
			91,449
5/3/2007		2,500	88,949
5/3/2007		1,000	87,949
5/3/2007	100	1,100	86,849
5/3/2007	100		86,949
5/3/2007	100		87,049
5/3/2007	500		87,549
5/4/2007		1,000	86,549
5/4/2007		1,000	85,549
5/4/2007		2,000	83,549
5/4/2007		300	83,249
5/4/2007		351	82,898
5/4/2007		349	82,549
5/7/2007	500		83,049
5/7/2007	500		83,549
5/7/2007		4,577	78,972
5/7/2007	1,500	-,	80,472
5/7/2007	500		80,972
5/7/2007	500		81,472
5/7/2007	1,500		82,972
5/7/2007	1,500	400	82,572
5/7/2007		2,000	80,572
5/7/2007			
	100	1,500	79,072
5/7/2007	100		79,172
5/7/2007	400		79,572
5/7/2007	100		79,672
5/7/2007	100		79,772
5/7/2007	100		79,872
5/7/2007	100		79,972
5/7/2007	100		80,072
5/7/2007	500		80,572
5/7/2007	200		80,772
5/7/2007	100		80,872
5/7/2007	100		80,972
5/7/2007	100		81,072
5/7/2007	500		81,572
5/8/2007		600	80,972
5/8/2007		100	80,872
2.3.2007		100	23,072

5/8/2007 100 80,772

5/8/2007		800	79,972
5/8/2007		400	79,572
5/8/2007	200		79,772
5/8/2007	300		80,072
5/8/2007	1,100		81,172
5/8/2007	300		81,472
5/8/2007	200		81,672
5/8/2007	130		81,802
5/8/2007	270		82,072
5/8/2007	100		82,172
5/8/2007	100		82,272
5/8/2007	800		83,072
5/8/2007	250		83,322
5/9/2008		2,700	80,622
5/9/2008		1,000	79,622
5/9/2008		1,500	78,122
5/9/2008		23	78,099
5/9/2008	1,500		79,599
5/9/2008	1,000	500	79,099
5/9/2008		100	78,999
5/9/2008		100	78,899
5/9/2008		300	78,599
5/9/2008		100	78,499
5/9/2008		100	78,399
5/9/2008		100	78,299
5/9/2008		200	78,099
5/9/2008		100	77,999
5/9/2008		100	77,899
5/9/2008	450		78,349
5/10/2007	2,500		80,849
5/10/2007	1,000		81,849
5/10/2007	2,000		83,849
5/10/2007	_,,,,,	2,500	81,349
5/10/2007	223	2,000	81,572
5/10/2007	1,477		83,049
5/10/2007	200		83,249
5/11/2007	500		83,749
5/11/2007		4,200	79,549
5/11/2007		500	79,049
5/11/2007	50		79,099
5/14/2007	2,500		81,599
5/14/2007	2,500		84,099
5/14/2007	1,500		85,599
5/14/2007	1,000		86,599
5/14/2007	200		86,799
5/14/2007	200	1,500	85,299
5/14/2007	100	1,500	85,399
5/14/2007	100	1,000	84,399
2, 1 <b>2</b> 007		1,000	0.,577

5/14/2007 200 84,599

5/14/2007	300		94 900
5/14/2007 5/14/2007	300	5,000	84,899
5/14/2007		5,000	79,899
5/14/2007		4,179 65	75,720
			75,655
5/14/2007		800	74,855
5/14/2007		2,000	72,855
5/14/2007	200	100	72,755
5/14/2007	300		73,055
5/14/2007	100		73,155
5/14/2007	200		73,355
5/14/2007	100		73,455
5/14/2007	100		73,555
5/14/2007	800		74,355
5/14/2007	500		74,855
5/14/2007	300		75,155
5/14/2007	300		75,455
5/14/2007	100		75,555
5/14/2007	10		75,565
5/14/2007	490		76,055
5/14/2007	100		76,155
5/14/2007	100		76,255
5/14/2007	4,000		80,255
5/14/2007	1,000		81,255
5/14/2007	100		81,355
5/14/2007	470		81,825
5/14/2007	1,000		82,825
5/14/2007	21		82,846
5/15/2007		900	81,946
5/15/2007		100	81,846
5/15/2007		1,000	80,846
5/15/2007		1,500	79,346
5/15/2007		1,500	77,846
5/15/2007	500	,	78,346
5/15/2007	2,500		80,846
5/15/2007	300		81,146
5/15/2007	200	1,500	79,646
5/15/2007		1,000	78,646
5/15/2007		800	77,846
5/15/2007		400	77,446
5/15/2007		500	76,946
5/15/2007		100	76,846
5/15/2007		100	76,746
5/15/2007		200	76,746 76,546
5/15/2007		200	76,346
5/16/2007	1,500	200	70,346 77,846
5/16/2007			
	1,000		78,846
5/16/2007	1,000		79,846
5/16/2007	405		80,251

5/16/2007 595 80,846

5/1/6/0007	1.500		00.246
5/16/2007	1,500		82,346
5/16/2007	600	4 700	82,946
5/16/2007		1,500	81,446
5/17/2007	1,000		82,446
5/17/2007	1,000		83,446
5/17/2007	500		83,946
5/18/2007		1,100	82,846
5/18/2007		1,800	81,046
5/18/2007		2,404	78,642
5/18/2007		1,396	77,246
5/18/2007		1,000	76,246
5/18/2007		500	75,746
5/18/2007		1,000	74,746
5/18/2007		2,500	72,246
5/18/2007	2,000	,	74,246
5/18/2007	1,500		75,746
5/18/2007	1,500	500	75,246
5/18/2007		100	75,146
5/18/2007		151	74,995
5/18/2007		800	74,195
5/18/2007		1,700	72,495
5/18/2007		200	72,493
5/18/2007		100	72,195
5/18/2007		100	72,095
5/18/2007		200	71,895
5/18/2007		100	71,795
5/18/2007		75	71,720
5/18/2007		1,200	70,520
5/18/2007		25	70,495
5/18/2007		400	70,095
5/18/2007	100		70,195
5/18/2007	28		70,223
5/18/2007	72		70,295
5/21/2007		2,316	67,979
5/21/2007		200	67,779
5/21/2007		100	67,679
5/21/2007		44	67,635
5/21/2007	100		67,735
5/21/2007	100		67,835
5/21/2007	300		68,135
5/22/2007	650		68,785
5/22/2007	2,500		71,285
5/22/2007	1,500		72,785
5/22/2007	450		73,235
5/22/2007	210		73,445
5/23/2007	1,000		74,445
5/23/2007	800		75,245
5/23/2007	200		75,245
314314007	200		13,443

5/23/2007	400	75,845
3/23/2007	400	13,643

5/23/2007	100		75,945
5/23/2007	1,100		77,045
5/23/2007	350		77,395
5/23/2007	300		77,695
5/23/2007	150		77,845
5/24/2007	500		78,345
5/24/2007		1,000	77,345
5/24/2007		1,500	75,845
5/24/2007		1,500	74,345
5/24/2007	500		74,845
5/24/2007		1,500	73,345
5/24/2007		108	73,237
5/24/2007		100	73,137
5/24/2007		291	72,846
5/25/2007	500		73,346
5/25/2007	1,000		74,346
5/25/2007	500		74,846
5/25/2007	600		75,446
5/25/2007	100		75,546
5/25/2007	300		75,846
5/29/2007	2,000		77,846
5/29/2007	2,000	3,500	74,346
5/29/2007	100	3,300	74,446
5/29/2007	200		74,646
5/29/2007	200		74,846
5/30/2007	500		75,346
5/30/2007	1,000		76,346
5/30/2007	1,000		77,346
5/30/2007	1,500		78,846
5/30/2007	500		
	300	1 000	79,346
5/30/2007		1,000	78,346
5/30/2007		1,000	77,346
5/30/2007		1,000	76,346
5/31/2007		2,900	73,446
5/31/2007		1,100	72,346
5/31/2007		1,350	70,996
5/31/2007		1,000	69,996
5/31/2007		650	69,346
5/31/2007	150		69,496
6/1/2007		100	69,396
6/1/2007		1,900	67,496
6/1/2007		400	67,096
6/1/2007		600	66,496
6/1/2007		1,000	65,496
6/1/2007		500	64,996
6/1/2007		500	64,496
6/1/2007	1,000		65,496
6/1/2007	55		65,551

6/1/2007	00	65,651
----------	----	--------

6/1/2007	100		65,751
6/1/2007	100		65,851
6/1/2007	45		65,896
6/1/2007	100		65,996
6/1/2007	1,100		67,096
6/1/2007	400		67,496
6/1/2007	500		67,996
6/1/2007	500		68,496
6/1/2007	850		69,346
6/4/2007	1,500		70,846
6/5/2007	500		71,346
6/6/2007	300	1,500	69,846
6/6/2007	300	1,500	70,146
6/6/2007	200		70,346
6/6/2007	300		70,646
			•
6/6/2007	1,000		71,646
6/6/2007	500		72,146
6/6/2007	700		72,846
6/6/2007	300		73,146
6/6/2007	500		73,646
6/6/2007	500		74,146
6/7/2007	1,500		75,646
6/7/2007	500		76,146
6/7/2007	200		76,346
6/7/2007	100		76,446
6/7/2007	446		76,892
6/8/2007		200	76,692
6/11/2007	1,000		77,692
6/11/2007	200		77,892
6/11/2007		1,500	76,392
6/11/2007		1,500	74,892
6/11/2007		900	73,992
6/11/2007		100	73,892
6/11/2007		100	73,792
6/11/2007		100	73,692
6/11/2007		100	73,592
6/11/2007		800	72,792
6/11/2007		548	72,244
6/11/2007	300		72,544
6/11/2007	300		72,844
6/12/2007		1,100	71,744
6/12/2007	1,500	1,100	73,244
6/12/2007	2,500		75,744
6/12/2007	2,400		78,144
6/12/2007	100		78,244
6/12/2007	100	500	77,744
6/12/2007		800	76,944
			·
6/12/2007		4,900	72,044

6/13/2007 200 72,244	6/13/2007	200	72,244
----------------------	-----------	-----	--------

6/13/2007	200		72,444
6/13/2007	300	400	72,744
6/13/2007	•••	498	72,246
6/13/2007	200		72,446
6/14/2007	1,500		73,946
6/14/2007	1,000		74,946
6/14/2007	500		75,446
6/14/2007	300		75,746
6/14/2007	200		75,946
6/14/2007		2,500	73,446
6/14/2007	200		73,646
6/14/2007		1,000	72,646
6/14/2007	1,000		73,646
6/14/2007	100		73,746
6/14/2007	200		73,946
6/14/2007	100		74,046
6/14/2007	100		74,146
6/14/2007	100		74,246
6/14/2007	200		74,446
6/14/2007	200		74,646
6/14/2007	100		74,746
6/14/2007	100		74,846
6/14/2007	100		74,946
6/14/2007	100		75,046
6/14/2007	200		75,246
6/14/2007	300		75,546
6/15/2007		200	75,346
6/15/2007	100		75,446
6/15/2007	2,500		77,946
6/15/2007		1,000	76,946
6/15/2007		3,000	73,946
6/15/2007	200		74,146
6/15/2007	300		74,446
6/18/2007		1,400	73,046
6/18/2007		900	72,146
6/18/2007		3,200	68,946
6/18/2007		1,358	67,588
6/18/2007		1,142	66,446
6/18/2007		100	66,346
6/18/2007		63	66,283
6/18/2007		100	66,183
6/18/2007		100	66,083
6/18/2007		1,000	65,083
6/18/2007		1,000	64,083
6/18/2007		100	63,983
6/18/2007		100	63,883
6/18/2007		100	63,783
6/18/2007		100	63,683
J. 10, 200 I		100	05,005

6/18/2007 100 63,583

6/18/2007	100	63,483
6/18/2007	100	63,383
6/18/2007	800	62,583
6/18/2007	100	62,683
6/18/2007	100	62,783
6/18/2007	100	62,883
6/18/2007	300	63,183
6/18/2007	100	63,283
6/18/2007	200	63,483
6/18/2007	200	63,683
6/19/2007	2,500	66,183
6/19/2007	1,500	67,683
6/19/2007	500	68,183
6/19/2007	1,000	69,183
6/19/2007	500	69,683
6/19/2007	2,400	
6/19/2007	200	
6/19/2007	400	· · · · · · · · · · · · · · · · · · ·
6/19/2007	100	
	100	,
6/19/2007		,
6/19/2007	100	,
6/19/2007	400	,
6/19/2007	100	·
6/19/2007	100	65,783
6/19/2007	200	65,583
6/19/2007	100	65,483
6/19/2007	300	65,183
6/19/2007	100	65,083
6/19/2007	200	•
6/19/2007	100	64,983
6/19/2007	100	65,083
6/19/2007	500	65,583
6/19/2007	100	65,683
6/19/2007	200	65,883
6/19/2007	100	65,983
6/19/2007	100	66,083
6/19/2007	100	66,183
6/19/2007	100	66,283
6/19/2007	100	66,383
6/19/2007	100	66,483
6/19/2007	540	67,023
6/19/2007	100	67,123
6/19/2007	200	67,323
6/19/2007	60	67,383
6/19/2007	300	67,683
6/19/2007	600	68,283
6/19/2007	100	68,383
6/20/2007	500	68,883
012012007	300	00,003

6/20/2007 3,400 72,283

6 10 0 10 0 0 T	100		<b>=2.2</b> 22
6/20/2007	100		72,383
6/20/2007	1,000	2 000	73,383
6/20/2007	<b>7</b> 00	2,000	71,383
6/20/2007	500		71,883
6/20/2007	1,400		73,283
6/20/2007	100		73,383
6/20/2007	100		73,483
6/20/2007	100		73,583
6/20/2007	200		73,783
6/20/2007	100		73,883
6/20/2007	150		74,033
6/20/2007	350		74,383
6/20/2007	100		74,483
6/20/2007	200		74,683
6/20/2007	100		74,783
6/20/2007	100		74,883
6/20/2007	300		75,183
6/20/2007	363		75,546
6/21/2007	1,000		76,546
6/21/2007	200		76,746
6/21/2007	1,800		78,546
6/21/2007	1,000		79,546
6/21/2007	1,500		81,046
6/21/2007	1,500		82,546
6/21/2007	1,000		83,546
6/21/2007	200		83,746
6/21/2007	500		84,246
6/21/2007	300	1,634	82,612
6/21/2007	1,000	1,034	83,612
6/21/2007	500		
	300	2 000	84,112
6/21/2007		2,000	82,112
6/21/2007		100	82,012
6/21/2007		100	81,912
6/21/2007		100	81,812
6/21/2007		100	81,712
6/21/2007		100	81,612
6/21/2007		100	81,512
6/21/2007		100	81,412
6/21/2007		100	81,312
6/21/2007		7,400	73,912
6/21/2007		1,600	72,312
6/21/2007		800	71,512
6/21/2007		2,000	69,512
6/21/2007	135		69,647
6/21/2007	65		69,712
6/21/2007	100		69,812
6/21/2007	100		69,912
6/21/2007	100		70,012
			*

6/21/2007	200	70,212
-----------	-----	--------

6/21/2007	100		70,312
6/21/2007	100		70,412
6/21/2007	100		70,512
6/21/2007	10		70,522
6/21/2007	90		70,612
6/21/2007	1,300		·
	-		71,912
6/21/2007	300		72,212
6/21/2007	100		72,312
6/21/2007	170		72,482
6/21/2007	30		72,512
6/21/2007	70		72,582
6/21/2007	100		72,682
6/21/2007	100		72,782
6/21/2007	100		72,882
6/21/2007	830		73,712
6/21/2007	100		73,812
6/21/2007	100		73,912
6/21/2007	100		74,012
6/21/2007	100		74,112
6/21/2007	100		74,212
6/21/2007	100		74,312
6/21/2007	100		74,412
6/21/2007	2,000		76,412
6/21/2007	100		·
			76,512
6/21/2007	100		76,612
6/21/2007	100		76,712
6/21/2007	100		76,812
6/21/2007	100		76,912
6/21/2007	100		77,012
6/21/2007	100		77,112
6/22/2007	2,500		79,612
6/22/2007	1,500		81,112
6/22/2007	1,500		82,612
6/22/2007	2,500		85,112
6/22/2007	100		85,212
6/22/2007	100		85,312
6/22/2007	100		85,412
6/22/2007	700		86,112
6/22/2007	250		86,362
6/25/2007	400		86,762
6/25/2007	1,600		88,362
6/25/2007	1,000	1,000	87,362
6/25/2007	1,000	1,000	88,362
6/25/2007	600		
			88,962
6/25/2007	400	1 000	89,362
6/25/2007		1,000	88,362
6/25/2007		5,000	83,362
6/25/2007		1,250	82,112

6/25/2008 100 82,012

6/25/2007	300		82,312
6/26/2007		100	82,212
6/26/2007		1,535	80,677
6/26/2007		100	80,577
6/26/2007	200		80,777
6/26/2007	300		81,077
6/27/2007	500		81,577
6/27/2007	300		81,877
6/27/2007	900		82,777
6/27/2007	600		83,377
6/27/2007	100		83,477
6/27/2007	100		83,577
6/27/2007	100		83,677
6/27/2007	100		83,777
6/27/2007	100		83,877
6/27/2007	100		83,977
6/27/2007	100		84,077
6/27/2007	100		84,177
6/27/2007	300		84,477
6/27/2007	500		84,977
6/27/2007	500		85,477
6/27/2007	500		85,977
6/27/2007	300		86,277
6/27/2007	300		86,577
6/27/2007	900		87,477
6/27/2007	100		87,577
6/27/2007	400		87,977
6/27/2007	300		88,277
6/27/2007	200		88,477
6/27/2007	300		88,777
6/27/2007	100		88,877
6/27/2007	100		88,977
6/27/2007	100		89,077
6/27/2007	100		89,177
6/27/2007	100		89,277
6/27/2007	100		89,377
6/27/2007	100		89,477
6/27/2007	400		89,877
6/27/2007	49		89,926
6/27/2007	100		90,026
6/27/2007	251		90,277
6/27/2007	200		90,477
6/27/2007	100		90,577
6/27/2007	100		90,677
6/27/2007	100		90,777
6/27/2007	100		90,777
6/27/2007	100		90,877
6/27/2007	1,000		90,977
012112001	1,000		71,7//

6/27/2007 1,000 92,977

6/27/2007		2,300	90,677
6/28/2007		1,500	89,177
6/28/2007		3,400	85,777
6/28/2007		100	85,677
6/28/2007		2,900	82,777
6/28/2007		500	82,277
6/28/2007		1,000	81,277
6/28/2007	100		81,377
6/28/2007	100		81,477
6/28/2007	100		81,577
6/28/2007	200		81,777
6/28/2007	100		81,877
6/28/2007	100		81,977
6/28/2007	1,500		83,477
6/28/2007	100		83,577
6/28/2007	700		84,277
6/28/2007	500		84,777
6/29/2007		2,500	82,277
6/29/2007		370	81,907
6/29/2007		700	81,207
6/29/2007		895	80,312
6/29/2007		585	79,727
6/29/2007		300	79,427
6/29/2007		41	79,386
6/29/2007		100	79,286
6/29/2007		1,850	77,436
6/29/2007		415	77,021
7/2/2007	100	.10	77,121
7/2/2007	600		77,721
7/2/2007	800		78,521
7/2/2007	1,500		80,021
7/2/2007	400		80,421
7/2/2007	44		80,465
7/2/2007	400		80,865
7/2/2007	100		80,965
7/2/2007	100	400	80,565
7/2/2007	500	100	81,065
7/2/2007	500		81,565
7/2/2007	590		82,155
7/2/2007	1,000		83,155
7/2/2007	1,000	1,200	81,955
7/3/2008	1,000	1,200	82,955
7/3/2008	1,000		83,955
7/3/2008	500		84,455
7/3/2007	500		84,955
7/3/2007	100		85,055
7/3/2007	200		85,255
7/3/2007	200		85,455
11312001	200		05,755

7/3/2007	500	85,955

300		86,255
300		86,555
400		86,955
500		87,455
200		87,655
300		87,955
		88,455
		88,955
	1.000	87,955
		87,655
200		87,855
		87,955
		88,055
		88,155
		88,655
		88,855
		88,955
		89,055
		89,155
		90,155
		90,655
		91,155
		91,655
		92,655
		93,655
1,000	2.700	90,955
		89,955
		84,655
		84,355
		83,455
		83,055
400	100	82,955
		83,355
		83,855
		84,855
		85,855
		86,255
		87,355
1,000	100	88,355
<b>7</b> 00	100	88,255
		88,755
		89,255
		89,305
450	<b>7</b> 00	89,755
		89,255
		88,255
		87,255
	800	86,455
	300 400 500	300 400 500 200 300 500 500 1,000 300 200 100 100 100 100 100 100 1

7/16/2007 200 86,255

	4.0.0		
7/16/2007	100		86,355
7/16/2007	100		86,455
7/16/2007	700		87,155
7/17/2007		500	86,655
7/17/2007		400	86,255
7/17/2007		400	85,855
7/17/2007		3,700	82,155
7/17/2007	600		82,755
7/17/2007	350		83,105
7/17/2007	20		83,125
7/17/2007	130		83,255
7/17/2007	500		83,755
7/17/2007	200		83,955
7/18/2007	169		84,124
7/18/2007	831		84,955
7/18/2007		3,000	81,955
7/18/2007	1,000	-,	82,955
7/18/2007	500		83,455
7/18/2007	300		83,755
7/18/2007	100		83,855
7/18/2007	100		83,955
7/18/2007	100		84,055
7/18/2007	100		84,155
7/18/2007	100		84,255
7/18/2007	200		84,455
7/19/2007	36		84,491
7/19/2007	164		84,655
7/19/2007	104	200	84,455
7/19/2007		2,000	82,455
7/19/2007	500	2,000	82,955
7/19/2007	1,000		83,955
7/19/2007	1,000		84,055
			· ·
7/19/2007	100		84,155
7/19/2007	100		84,255
7/19/2007	100		84,355
7/19/2007	100		84,455
7/19/2007	100		84,555
7/19/2007	100	1.500	84,655
7/20/2007		1,500	83,155
7/20/2007		2,100	81,055
7/20/2007		700	80,355
7/20/2007		900	79,455
7/20/2007		100	79,355
7/20/2007		1,027	78,328
7/20/2007		100	78,228
7/20/2007		100	78,128
7/20/2007		150	77,978
7/23/2007		1,000	76,978

7/23/2007 500 77,478

7/23/2007	250		77,728
7/23/2007	100		77,828
7/23/2007	500		78,328
7/23/2007	150		78,478
7/23/2007	477		78,955
7/24/2007	700		79,655
7/24/2007	400		80,055
7/24/2007	100		80,155
7/24/2007	500		80,655
7/24/2007	1,000		81,655
7/24/2007	500		82,155
7/24/2007	500		82,655
7/24/2007	50		82,705
7/24/2007	150		82,855
7/25/2007		100	82,755
7/25/2007		100	82,655
7/25/2007		500	82,155
7/25/2007		8,200	73,955
7/27/2007	500		74,455
7/27/2007	1,000		75,455
7/27/2007	1,000		76,455
7/30/2007	500		76,955
7/30/2007		1,500	75,455
7/30/2007		10	75,445
7/30/2007		100	75,345
7/30/2007		100	75,245
7/30/2007		100	75,145
7/30/2007		200	74,945
7/30/2007		100	· ·
			74,845
7/30/2007		400	74,445
7/30/2007		300	74,145
7/30/2007		90	74,055
7/30/2007		100	73,955
7/30/2007		350	73,605
7/31/2007		1,500	72,105
7/31/2007	149		72,254
7/31/2007	100		72,354
7/31/2007	200		72,554
7/31/2007	200		72,754
7/31/2007	300		73,054
8/1/2007	1,000		74,054
8/1/2007	1,500		75,554
8/1/2007	1,500		77,054
8/1/2007	2,500		79,554
8/1/2007	1,500		81,054
8/1/2007	2,000		83,054
8/1/2007	1,000		84,054
8/1/2007	100		84,154
0/1/200/	100		04,134

8/1/2007 1 84,155

0/1/2007	00		04.254
8/1/2007	99		84,254
8/1/2007	1	<b>5</b> 000	84,255
8/2/2007	1.500	5,000	79,255
8/3/2007	1,500		80,755
8/3/2007	2,000	1.000	82,755
8/3/2007		1,800	80,955
8/3/2007		850	80,105
8/3/2007		1,960	78,145
8/3/2007		200	77,945
8/3/2007		100	77,845
8/3/2007		90	77,755
8/3/2007		172	77,583
8/3/2007		4,078	73,505
8/3/2007		100	73,405
8/3/2007		100	73,305
8/3/2007		100	73,205
8/3/2007		100	73,105
8/3/2007		5,000	68,105
8/3/2007		1,000	67,105
8/3/2007		1,000	66,105
8/3/2007		100	66,005
8/3/2007		500	65,505
8/3/2007		500	65,005
8/3/2007		100	64,905
8/3/2007		465	64,440
8/3/2007		150	64,290
8/3/2007		500	63,790
8/3/2007		100	63,690
8/3/2007		100	63,590
8/3/2007		85	63,505
8/3/2007	2,500		66,005
8/3/2007	2,500		68,505
8/3/2007	100		68,605
8/3/2007	300		68,905
8/3/2007	100		69,005
8/3/2007	2,000		71,005
8/3/2007	500		71,505
8/3/2007	100		71,605
8/3/2007	400		72,005
8/6/2007	1,000		73,005
8/6/2007	1,000		74,005
8/6/2007		1,000	73,005
8/6/2007	150	•	73,155
8/6/2007	100		73,255
8/7/2007	500		73,755
8/7/2007		1,100	72,655
8/7/2007		4,000	68,655
8/7/2007		100	68,555
			,

8/7/2007	500		69,543
8/7/2007	300		69,843
8/7/2007	200		70,043
8/7/2007	2,000		72,043
8/7/2007	55		72,098
8/7/2007	45		72,143
8/7/2007	100		72,243
8/7/2007	100		72,343
8/7/2007	100		72,443
8/7/2007	100		72,543
8/7/2007	500		73,043
8/7/2007	81		73,124
8/7/2007	100		73,224
8/7/2007	100		73,324
8/7/2007	2,219		75,543
8/7/2007	1,500		77,043
8/7/2007	100		77,143
8/7/2007	200		77,343
8/7/2007	100		77,443
8/7/2007	250		77,693
8/8/2008		1,000	76,693
8/8/2008		1,000	75,693
8/8/2008		100	75,593
8/8/2008		1,900	73,693
8/8/2008	500	1,500	74,193
8/8/2008	500		74,693
8/8/2008	250		74,943
8/9/2007	250		75,193
8/9/2007	237		75,430
8/13/2007	231	1,288	74,142
8/13/2007		700	73,442
8/13/2007		300	73,142
8/13/2007		937	72,205
8/13/2007		1,300	70,905
8/13/2007		100	70,805
8/13/2007		400	70,405
8/13/2007	500	400	70,403
8/13/2007	500		*
			71,405
8/13/2007 8/13/2007	1,500		72,905
	200		73,105
8/13/2007	200		73,305
8/14/2007	100		73,405
8/14/2007	300		73,705
8/14/2007	200		73,905
8/14/2007	100		74,005
8/14/2007	100		74,105
8/14/2007	100		74,205
8/14/2007	100		74,305

100	74.405
1 ()()	/4 403
	100

8/14/2007	500		74,905
8/15/2007	500		75,405
8/16/2007	1,000		76,405
8/16/2007	1,000		77,405
8/16/2007	300		77,705
8/16/2007	200		77,905
8/16/2007	200	700	77,205
8/16/2007		200	77,005
8/16/2007		100	76,905
8/16/2007		300	76,605
	200	300	
8/17/2007	200		76,805
8/17/2007	300		77,105
8/17/2007	500		77,605
8/17/2007	1,500	2 000	79,105
8/17/2007		2,000	77,105
8/17/2007	300		77,405
8/17/2007	200		77,605
8/20/2007	2,000		79,605
8/20/2007	3,000		82,605
8/20/2007	2,100		84,705
8/20/2007	400		85,105
8/20/2007	1,500		86,605
8/20/2007	200		86,805
8/20/2007	300		87,105
8/20/2007	200		87,305
8/20/2007	200		87,505
8/21/2007	1,000		88,505
8/21/2007	1,000		89,505
8/22/2007	500		90,005
8/23/2007	1,500		91,505
8/23/2007	600		92,105
8/23/2007	600		92,705
8/24/2007	000	5,000	87,705
		5,000	•
8/24/2007		5,000	82,705
8/27/2008		600	82,105
8/27/2008		300	81,805
8/27/2008		4,000	77,805
8/27/2008		2,100	75,705
8/27/2008		50	75,655
8/27/2008		3,850	71,805
8/27/2008		100	71,705
8/27/2008		100	71,605
8/27/2008		100	71,505
8/27/2008		190	71,315
8/27/2008		100	71,215
8/27/2008		100	71,115
8/27/2008		6,000	65,115
8/27/2008		100	65,015
		_ 00	,

8/27/2008 2,910 62,105

8/27/2008	1,000		63,105
8/27/2008	300		63,405
8/27/2008	200		63,605
8/27/2008	300		63,905
8/28/2007		1,654	62,251
8/28/2007		846	61,405
8/28/2007		500	60,905
8/28/2007		200	60,705
8/28/2007			
		3,100	57,605
8/28/2007		100	57,505
8/28/2007	•00	100	57,405
8/30/2007	200		57,605
8/30/2007	100		57,705
8/30/2007	2,145		59,850
8/30/2007	2,555		62,405
8/30/2007	500		62,905
8/30/2007	2,445		65,350
8/30/2007	955		66,305
8/30/2007	100		66,405
8/30/2007	2,500		68,905
8/30/2007	700		69,605
8/30/2007	1,800		71,405
8/30/2007	,	5,000	66,405
8/30/2007	2,000	-,,,,,	68,405
8/30/2007	2,000	200	68,205
8/30/2007	1,100	200	69,305
8/30/2007	300		69,605
8/30/2007	300	100	69,505
8/30/2007		900	68,605
8/30/2007		100	68,505
8/30/2007		406	68,099
9/4/2007		5,000	63,099
9/4/2007		2,500	60,599
9/4/2007		2,500	58,099
9/4/2007		2,500	55,599
9/4/2007		1,200	54,399
9/5/2007	10,000		64,399
9/5/2007	3,000		67,399
9/5/2007	300		67,699
9/5/2007	3,200		70,899
9/5/2007	1,290		72,189
9/5/2007		894	71,295
9/5/2007	200		71,495
9/7/2007	1,500		72,995
9/7/2007	,- • •	1,200	71,795
9/7/2007		700	71,095
9/7/2007		100	70,995
9/7/2007		200	70,795
11114001		200	10,193

9/7/2007 1,500 69,295

9/10/2007		1,000	68,295
9/10/2007		11,000	57,295
9/10/2007		2,000	55,295
9/10/2007		1,000	54,295
9/10/2007		600	53,695
9/10/2007		1,200	52,495
9/10/2007		200	52,295
9/10/2007		905	51,390
9/10/2007	4,000		55,390
9/10/2007	5,000		60,390
9/10/2007	2,500		62,890
9/10/2007	200		63,090
9/10/2007	100		63,190
9/11/2007	5,000		68,190
9/11/2007	500		68,690
9/11/2007	1,500		70,190
9/11/2007	200		70,390
9/11/2007	400		70,790
9/11/2007	500		71,290
9/12/2007	1,500		72,790
9/13/2007	500		73,290
9/13/2007	1,000		74,290
9/13/2007	1,000	200	74,090
9/13/2007		100	73,990
9/13/2007		100	73,890
9/13/2007		100	73,790
9/13/2007		200	73,590
9/13/2007		100	73,490
9/13/2007		373	73,490
9/13/2007		127	72,990
9/13/2007	1,000	127	72,990
9/14/2007	1,000	500	73,490
9/14/2007		100	73,390
9/14/2007		100	73,290
9/14/2007	200	100	73,190
9/14/2007	200		73,390
9/14/2007	100		73,490
9/14/2007	800		74,290
9/14/2007	100	1 000	74,390
9/17/2007		1,000	73,390
9/17/2007		5,000	68,390
9/17/2007		1,295	67,095
9/17/2007		2,000	65,095
9/17/2007		1,200	63,895
9/17/2007		1,400	62,495
9/17/2007	200		62,695
9/18/2007		6,390	56,305
9/18/2007		100	56,205

9/18/2007 200 56,005

Edgar Filing: Shack Herbert Michael - Form PRRN14A

9/18/2007		100	55,905
9/18/2007		400	55,505
9/18/2007	500		56,005
9/18/2007	200		56,205
9/18/2007	100		56,305
9/18/2007	100		56,405
9/18/2007	200		56,605
9/18/2007	100		56,705
9/19/2007	1,000		57,705
9/19/2007	1,000		58,705
9/19/2007	400		59,105
9/19/2007	1,600		60,705
9/19/2007	2,000		62,705
9/19/2007	400		63,105
9/19/2007	300		63,405
9/20/2007		4,400	59,005
9/20/2007	1,500		60,505
9/24/2007	1,000		61,505
9/24/2007	500		62,005
9/24/2007	500		62,505
9/24/2007	2,000		64,505
9/24/2007		5,200	59,305
9/24/2007		400	58,905
9/24/2007		100	58,805
9/24/2007		100	58,705
9/24/2007		5,200	53,505
9/24/2007		2,600	50,905
9/24/2007		1,000	49,905
9/24/2007		361	49,544
9/24/2007		100	49,444
9/24/2007			